cDNA ENCODING A NOVEL HUMAN PROTEIN TYROSINE PHOSPHATASE

Abstract: A novel human protein tyrosine phosphatase (PTP) has been identified and its cDNA has been isolated. This novel PTP, denoted PTP-OB, has a receptor-like three dimensional structure and is present in osteoblasts. PTP-OB is involved in osteoblast differentiation, and modulators of PTP-OB activity in turn modulate osteoblast differentiation, osteoclast differentiation and osteoclast activity.

Description: TITLE OF THE DISCLOSURE cDNA ENCODING A NOVEL HUMAN PROTEIN TYROSINE PHOSPHATASE BACKGROUND OF THE INVENTION Protein tyrosine phosphorylation plays an important role in the regulation of cellular signal transduction, cell growth and differentiation. The level of tyrosine phosphorylation is controlled by the equilibrium of the activities of the protein tyrosine kinases (PTK) and protein tyrosine phosphatases (PTP) (Cantley , L.C. et al., 1991 , Cell, 64, pp.281-302; Fischer, E.H. et al., 1991, Science, 253, pp.401 -406; Alexander, D.R. and Cantrell, D.A., 1989, Immunol. Today, 10, pp.200- 205; Tonks, N.K. and Charbonneau, H„ 1989, Trends Biochem.Sci., 14, pp.497-500; Saito, H. and Streuli, M. 1991. Cell Growth And Differentiation, 2, pp.59-65; Gautier, J. et al., 1991 , Cell, 67, pp.197-21 1 ; Zheng, X.M. et al-, Nature, 359, ρp.336-339). It is well documented that tyrosine kinase activities play an important role in the growth and the differentiation of bone cells. M-CSF and its receptor c-fms were shown to be crucial in osteoclast development. Recently Soriano et al . reported that disruption of c-src proto-oncogene, by homologous recombination, induced osteopetrosis, that is characterized by the reduction of bone resorption due to impairment of osteoclastic function (Soriano, P. et al-, 1991 , Cell, 64, pp.693-702; Boyce, B.F. et ak, 1992, J.Clin.Invest., 90, pp.1622- 1627). In both in vivo and in vitro experiments it was demonstrated that FGF, IGF-I and IGF-II are important for the osteoblast functions. These findings suggest that the control of tyrosine phosphorylation is clearly important for bone cells. As mentioned above, protein tyrosine phosphorylation is tightly balanced by the opposing actions of protein tyrosine kinases and protein tyrosine phosphatases. Treatment of bone cells with orthovanadate, a PTPase inhibitor, resulted in the stimulation of cell proliferation and the synthesis of bone collagen (Lau et al. Endocrinology, 1988, 123. pp. 2858-2867). In organ cultures, vanadate treatment inhibited the stimulation of bone resorption induced by treatment with PTH (Krieger and Tashjian, Endocrinology, 1983, 1 13. pp. 324-328). Taken together, these findings suggest that PTPases play an important function in bone cells. SUMMARY OF THE DISCLOSURE The polymerase chain reaction methodology was used to identify cDNA molecules for several PTPases in bone cells. One of these cDNA clones, named PTP-OB, encoded a novel member of the protein tyrosine phosphatase family. From human cDNA libraries, the entire open reading frame-encoding DNA was cloned for that protein. PTP-OB is composed of 1911 amino acid residues. Sequence analysis revealed two regions of hydrophobic amino acid residues that comprise a putative signal peptide and transmembrane domain, thus indicating PTP-OB as a receptor- like PTPase. The amino acid sequence of PTP-OB shows the best similarity to LAR and LAR related PTPases. As described for LAR, three immunoglobulin-like and eight fibronectin type Ill-like domains can be identified in the extracellular domain, and two tandem repeats of PTPase domains in the cytoplasmic region. The cDNA clones isolated from human brain library contained a deletion of 1227 bp that maintained the open reading frame, but coded for an extracellular region that was shorter by 409 amino acid residues and one with one amino acid substitution. Hybridization experiments revealed that PTP-OB was expressed as a 7.3 kilo base (kb) mRNA in both bone and brain tissues. The tissue distribution of PTP-OB transcript suggested that this receptor- like PTPase is involved in the growth and differentiation of osteoblasts and brain cells. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1. Schematic structure of PTP-OB overlapping cDNA clones were isolated from various human cDNA libraries: PTP-OB-17 from human fetal lung library, PTP-OB- 10 human giant cell tumor library and PTP-OB- 133 from human fetal brain library are shown, depicting the extracellular region with the signal peptide, the immunoglobulin-like domains (Ig-like), the fibronectin (FN) type Ill-like domains, the transmembrane (TM) domain and the cytoplasmic region with the PTPase domains. Figure 2. The nucleotide sequence of PTP-OB cDNA is shown. Figure 3. The amino acid sequence of PTP-OB is shown. Figure 4. Northern blots of RNA from human osteosarcoma (lane 1), human giant cell tumors (lanes 2-5) , and rat tibia (lane 6) cells is shown. Figure 5. A Northern blot of RNA from human tissues is shown. Figure 6. Northern blots of RNA from human tissues is shown on the left, and of RNA from human tumor tissue on the right two lanes: osteosarcoma (OS) and giant cell tumor (GCT). Figure 7. The effect of protein tyrosine phosphatases and protein tyrosine kinase in in vitro osteoclast formation is shown. Figure 8. The time dependent effect of orthovanadate on osteoclast cell fusion is shown. Figure 9. The effect of inhibitors of protein tyrosine phosphatases and protein tyrosine kinase on in vitro bone resorption is shown. DETAILED DESCRIPTION OF THE F VENTION The present invention relates to cDNA encoding a novel protein tyrosine phosphatase termed PTP-OB. The present invention is also related to recombinant host cells which express the cloned PTP-OB-encoding DNA contained in a recombinant expression plasmid. The present invention is also related to a method for the screening of substances which modulate PTP-OB protein activity. The DNA of the present invention is isolated from PTP-OB producing cells. PTP-OB, as used herein, refers to a protein tyrosine phosphatase which is specifically expressed in bone and brain cells. The present invention also relates to a unique protein tyrosine phosphatase protein, also described as PTP-OB, which is isolated from PTP-OB producing cells. PTP-OB protein, as used herein, refers to a protein tyrosine phosphatase protein which is specifically produced by bone and brain cells. Mammalian cells capable of producing PTP-OB include, but are not limited to, cells derived from bone such as MB 1.8 and brain cells such as U340. Transformed mammalian cell lines which produce PTP-OB include, but are not limited to, NIH 3T3 cells. The preferred cells for the present invention include normal human HELA, NIH 3T3, U2, and CHO cells and the most preferred cells are human 293 cells. Other cells and cell lines may also be suitable for use to isolate PTP-OB cDNA. Selection of suitable cells may be done by screening for PTP-OB produced by the cells. Methods for detecting PTP-OB activity are well known in the art (in: Maniatis, T., Fritsch, E.F., Sambrook, J., Molecular Cloning: A Laboratory Manual Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1982) and measure the level of PTP-OB RNA produced by the cells. Cells which possess PTP-OB activity in this assay may be suitable for the isolation of PTP-OB cDN A. Any of a variety of procedures may be used to clone PTP-OB cDNA. These methods include, but are not limited to, direct functional expression of the PTP-OB cDNA following the construction of an PTP-OB -containing cDNA library in an appropriate expression vector system. Another method is to screen an PTP-OB -containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a labelled oligonucleotide probe designed from the amino acid sequence of the PTP-OB protein. The preferred method consists of screening an PTP-OB -containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the PTP-OB protein. This partial cDNA is obtained by the specific PCR amplification of PTP-OB DNA fragments through the design of degenerate oligonucleotide primers from the amino acid sequence known for other PTP-OB-family protein tyrosine phosphatases which are related to the PTP-OB protein. It is readily apparent to those skilled in the art that other types of libraries, as well as libraries constructed from other cells or cell types, may be useful for isolating PTP-OB-encoding DNA. Other types of libraries include, but are not limited to, cDNA libraries derived from other cells or cell lines other than human such as mouse or rat cells, and genomic DNA libraries. It is readily apparent to those skilled in the art that suitable cDNA libraries may be prepared from cells or cell lines which have PTP-OB activity. The selection of cells or cell lines for use in preparing a cDNA library to isolate PTP-OB cDNA may be done by first measuring cell associated PTP-OB activity using the known assay cited above and used herein. Preparation of cDNA libraries can be performed by standard techniques well known in the art. Well known cDNA library construction techniques can be found for example, in Maniatis, T., Fritsch, E.F., Sambrook, J., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1982). It is also readily apparent to those skilled in the art that DNA encoding PTP-OB may also be isolated from a suitable genomic DNA library. Construction of genomic DNA libraries can be performed by standard techniques well known in the art. Well known genomic DNA library construction techniques can be found in Maniatis, T., Fritsch, E.F., Sambrook, J. in Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1982). In order to clone the PTP-OB gene by one of the preferred methods, the amino acid sequence or DNA sequence of PTP-OB or a homologous protein may be necessary. To accomplish this, PTP-OB protein or a homologous protein may be purified and partial amino acid sequence determined by automated sequenators. It is not necessary to determine the entire amino acid sequence, but the linear sequence of two regions of 6 to 8 amino acids can be determined for the PCR amplification of a partial PTP-OB DNA fragment. Once suitable amino acid sequences have been identified, the DNA sequences capable of encoding them are synthesized. Because the genetic code is degenerate, more than one codon may be used to encode a particular amino acid, and therefore, the amino acid sequence can be encoded by any of a set of similar DNA ohgonucleotides. Only one member of the set will be identical to the PTP-OB sequence but others in the set will be capable of hybridizing to PTP-OB DNA even in the presence of DNA ohgonucleotides with mismatches. The mismatched DNA ohgonucleotides may still sufficiently hybridize to the PTP-OB DNA to permit identification and isolation of PTP-OB encoding DNA. Using one of the preferred methods, cDNA clones encoding PTP-OB are isolated in a two-stage approach employing polymerase chain reaction (PCR) based technology and cDNA library screening. In the first stage, NH2-terminal and internal amino acid sequence information from the purified PTP-OB or a homologous protein is used to design degenerate oligonucleotide primers for the amplification of PTP-OB -specific DNA fragments. In the second stage, these fragments are cloned to serve as probes for the isolation of full length cDNA from a cDNA library derived from human osteosarcoma or brain cells. The sequence for the near full-length cDNA encoding PTP-OB is shown in Figure 2, and was designated clone PTP-OB. The deduced amino acid sequence of PTP-OB from the cloned cDNA is shown in Figure 3. Inspection of the determined cDNA sequence reveals the presence of a single, large open reading frame that encodes for an approximately 1911 amino acid protein. The cloned PTP-OB cDNA obtained through the methods described above may be recombinantly expressed by molecular cloning into an expression vector containing a suitable promoter and other appropriate transcription regulatory elements, and transferred into prokaryotic or eukaryotic host cells to produce recombinant PTP-OB. Techniques for such manipulations can be found described in Maniatis, T, et al., supra, and are well known in the art. Expression vectors are defined herein as DNA sequences that are required for the transcription of cloned DNA and the translation of their mRNAs in an appropriate host. Such vectors can be used to express eukaryotic DNA in a variety of hosts such as bacteria, bluegreen algae, plant cells, insect cells and animal cells. Specifically designed vectors allow the shuttling of DNA between hosts such as bacteria-yeast or bacteria-animal cells. An appropriately constructed expression vector should contain: an origin of replication for autonomous replication in host cells, selectable markers, a limited number of useful restriction enzyme sites, a potential for high copy number, and active promoters. A promoter is defined as a DNA sequence that directs RNA polymerase to bind to DNA and initiate RNA synthesis. A strong promoter is one which causes mRNAs to be initiated at high frequency. Expression vectors may include, but are not limited to, cloning vectors, modified cloning vectors, specifically designed plasmids or viruses. A variety of mammalian expression vectors may be used to express recombinant PTP-OB in mammalian cells. Commercially available mammalian expression vectors which may be suitable for recombinant PTP-OB expression, include but are not limited to, pMClneo (Stratagene), pXTl (Stratagene), pSG5 (Stratagene), pcDNAI, pcDNAIamp (Invitrogen), EBO-pSV2-neo (ATCC 37593) pBPV-l (8-2) (ATCC 371 10), pdBPV- MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), pUCTag (ATCC 37460), and 1ZD35 (ATCC 37565) DNA encoding PTP-OB may also be cloned into an expression vector for expression in a host cell. Host cells may be prokaryotic or eukaryotic, including but not limited to bacteria, yeast, mammalian cells including but not limited to cell lines of human, bovine, porcine, monkey and rodent origin, and insect cells including but not limited to drosophila derived cell lines. Cell lines derived from mammalian species which may be suitable and which are commercially available, include but are not limited to, CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26) and MRC-5 (ATCC CCL 171). The expression vector may be introduced into host cells via any one of a number of techniques including but not limited to transformation, transfection, protoplast fusion, and electroporation. The expression vector-containing cells are individually analyzed to determine whether they produce PTP-OB protein. Identification of PTP-OB expressing cells may be done by several means, including but not limited to immunological reactivity with anti-PTP-OB antibodies, and the presence of host cell-associated PTP-OB activity. Expression of PTP-OB DNA may also be performed using in vitro produced synthetic mRNA. Synthetic mRNA can be efficiently translated in various cell-free systems, including but not limited to wheat germ extracts and reticulocyte extracts, as well as efficiently translated in cell based systems, including but not limited to microinjection into frog oocytes, with microinjection into frog oocytes being preferred. To determine the PTP-OB cDNA sequence(s) that yields optimal levels of PTP-OB protein, PTP-OB cDNA molecules including but not limited to the following can be constructed: the full-length open reading frame of the PTP-OB cDN A and various constructs containing portions of the cDNA encoding only specific domains of the protein or rearranged domains of the protein. All constructs can be designed to contain none, all or portions of the 5' and/or 3' untranslated region of PTP- OB cDNA. PTP-OB activity and levels of protein expression can be determined following the introduction, both singly and in combination, of these constructs into appropriate host cells. Following determination of the PTP-OB cDNA cassette yielding optimal expression in transient assays, this PTP-OB cDNA construct is transferred to a variety of expression vectors (including recombinant viruses), including but not limited to those for mammalian cells, plant cells, insect cells, oocytes, bacteria, and yeast cells. Levels of PTP-OB protein in host cells is quantitated by a variety of techniques including, but not limited to, immunoaffinity and/or ligand affinity techniques. PTP-OB- specific affinity beads or PTP-OB -specific antibodies are used to isolate -^S-methionine labelled or unlabelled PTP-OB protein. Labelled PTP-OB protein is analyzed by SDS-PAGE. Unlabelled PTP-OB protein is detected by Western blotting, ELISA or RIA assays employing PTP-OB specific antibodies. Following expression of PTP-OB in a host cell, PTP- OB protein may be recovered to provide PTP-OB in active form. Several PTP-OB purification procedures are available and suitable for use. Recombinant PTP-OB may be purified from cell lysates and extracts, or from conditioned culture medium, by various combinations of, or individual application of salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography and hydrophobic interaction chromatography. In addition, recombinant PTP-OB can be separated from other cellular proteins by use of an immuno-affinity column made with monoclonal or polyclonal antibodies specific for full length PTP-OB, or polypeptide fragments of PTP-OB. Monospecific antibodies to PTP-OB are purified from mammalian antisera containing antibodies reactive against PTP- OB or are prepared as monoclonal antibodies reactive with PTP- OB using the technique of Kohler and Milstein, Nature 256: 495- 497 (1975). Monospecific antibody as used herein is defined as a single antibody species or multiple antibody species with homogenous binding characteristics for PTP-OB. Homogenous binding as used herein refers to the ability of the antibody species to bind to a specific antigen or epitope, such as those associated with the PTP-OB, as described above. PTP-OB specific antibodies are raised by immunizing animals such as mice, rats, guinea pigs, rabbits, goats, horses and the like, with an appropriate concentration of PTP-OB either with or without an immune adjuvant. Preimmune serum is collected prior to the first immunization. Each animal receives between about 0.1 μg and about 1000 μg of PTP-OB associated with an acceptable immune adjuvant. Such acceptable adjuvants include, but are not limited to, Freund's complete, Freund's incomplete, alum-precipitate, water in oil emulsion containing Corynebacterium parvum and tRNA. The initial immunization consists of the PTP-OB protein in, preferably, Freund's complete adjuvant at multiple sites either subcutaneously (SC), intraperitoneally (IP) or both. Each animal is bled at regular intervals, preferably weekly, to determine antibody titer. The animals may or may not receive booster injections following the initial immunizaiton. Those animals receiving booster injections are generally given an equal amount of PTP-OB in Freund's incomplete adjuvant by the same route. Booster injections are given at about three week intervals until maximal titers are obtained. At about 7 days after each booster immunization or about weekly after a single immunization, the animals are bled, the serum collected, and aliquots are stored at about -20°C. Monoclonal antibodies (mAb) reactive with PTP-OB are prepared by immunizing inbred mice, preferably Balb/c, with PTP-OB. The mice are immunized by the IP or SC route with about 1 μg to about 100 μg, preferably about 10 μg, of PTP-OB in about 0.5 ml buffer or saline incorporated in an equal volume of an acceptable adjuvant, as discussed above. Freund's complete adjuvant is preferred. The mice receive an initial immunization on day 0 and are rested for about 3 to about 30 weeks. Immunized mice are given one or more booster immunizations of about 1 to about 100 μg of PTP-OB in a buffer solution such as phosphate buffered saline by the intravenous (IV) route. Lymphocytes, from antibody positive mice, preferably splenic lymphocytes, are obtained by removing spleens from immunized mice by standard procedures known in the art. Hybridoma cells are produced by mixing the splenic lymphocytes with an appropriate fusion partner, preferably myeloma cells, under conditions which will allow the formation of stable hybridomas. Fusion partners may include, but are not limited to: mouse myelomas P3/NSl/Ag 4-1; MPC-11; S- 194 and Sp 2/0, with Sp 2/0 being preferred. The antibody producing cells and myeloma cells are fused in polyethylene glycol, about 1000 mol. wt., at concentrations from about 30% to about 50%. Fused hybridoma cells are selected by growth in hypoxanthine, thymidine and aminopterin supplemented Dulbecco's Modified Eagles Medium (DMEM) by procedures known in the art. Supernatant fluids are collected form growth positive wells on about days 14, 18, and 21 and are screened for antibody production by an immunoassay such as solid phase immunoradioassay (SPIRA) using PTP-OB as the antigen. The culture fluids are also tested in the Ouchterlony precipitation assay to determine the isotype of the mAb. Hybridoma cells from antibody positive wells are cloned by a technique such as the soft agar technique of MacPherson, Soft Agar Techniques, in Tissue Culture Methods and Applications, Kruse and Paterson, Eds., Academic Press, 1973. Monoclonal antibodies are produced in vivo by injection of pristane primed Balb/c mice, approximately 0.5 ml per mouse, with about 2 x 10" to about 6 x 10" hybridoma cells about 4 days after priming. Ascites fluid is collected at approximately 8- 12 days after cell transfer and the monoclonal antibodies are purified by techniques known in the art. In vitro production of an -PTP-OB mAb is carried out by growing the hydridoma in DMEM containing about 2% fetal calf serum to obtain sufficient quantities of the specific mAb. The mAb are purified by techniques known in the art. Antibody titers of ascites or hybridoma culture fluids are determined by various serological or immunological assays which include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent antibody (ELISA) technique and radioimmunoassay (RIA) techniques. Similar assays are used to detect the presence of PTP-OB in body fluids or tissue and cell extracts. It is readily apparent to those skilled in the art that the above described methods for producing monospecific antibodies may be utilized to produce antibodies specific for PTP-OB polypeptide fragments, or full-length PTP-OB polypeptide. PTP-OB antibody affinity columns are made by adding the antibodies to Affigel-10 (Biorad), a gel support which is pre-activated with N-hydroxysuccinimide esters such that the antibodies form covalent linkages with the agarose gel bead support. The antibodies are then coupled to the gel via amide bonds with the spacer arm. The remaining activated esters are then quenched with 1M ethanolamine HC1 (pH 8). The column is washed with water followed by 0.23 M glycine HC1 (pH 2.6) to remove any non-conjugated antibody or extraneous protein. The column is then equilibrated in phosphate buffered saline (pH 7.3) and the cell culture supernatants or cell extracts containing PTP- OB or PTP-OB fragments are slowly passed through the column. The column is then washed with phosphate buffered saline until the optical density (A280) f a -^ s t0 background, then the protein is eluted with 0.23 M glycine-HCl (pH 2.6). The purified PTP-OB protein is then dialyzed against phosphate buffered saline. The novel PTP-OB protein tyrosine phosphatase of the present invention is suitable for use in an assay procedure for the identification of compounds which modulate the PTP-OB activity. Modulating PTP-OB activity, as described herein includes the inhibition or activation of the protein and also includes directly or indirectly affecting the normal regulation of the PTP-OB activity. Compounds which modulate the PTP-OB activity include agonists, antagonists and compounds which directly or indirectly affect regulation of the PTP-OB activity. The PTP-OB protein tyrosine phosphatase of the present invention may be obtained from both native and recombinant sources for use in an assay procedure to identify PTP-OB modulators. In general, an assay procedure to identify PTP-OB modulators will contain the PTP- OB-protein of the present invention, and a test compound or sample which contains a putative PTP-OB modulator. The test compounds or samples may be tested directly on, for example, purified PTP-OB protein whether native or recombinant, subcellular fractions of PTP-OB- producing cells whether native or recombinant, and/or whole cells expressing the PTP-OB whether native or recombinant. The test compound or sample may be added to the PTP-OB in the presence or absence of a known PTP-OB modulator. The modulating activity of the test compound or sample may be determined by, for example, analyzing the ability of the test compound or sample to bind to PTP-OB protein, activate the protein, inhibit PTP-OB activity, inhibit or enhance the binding of other compounds to the PTP-OB protein, modifying receptor regulation, or modifying an intracellular activity. The identification of modulators of PTP-OB activity are useful in treating disease states involving the PTP-OB activity such as osteoporosis. Other compounds may be useful for stimulating or inhibiting activity of the receptor. These compounds are useful for the prevention and treatment of bone loss and the stimulation of bone formation. Such compounds could be of use in the treatment of diseases in which activation or inactivation of the PTP-OB protein results in either cellular proliferation, cell death, nonproliferation, induction of cellular neoplastic transformations or metastatic tumor growth and hence could be used in the prevention and/or treatment of cancers such as lung cancer and osteosarcoma. The isolation and purification of an PTP-OB- encoding DNA molecule would be useful for establishing the tissue distribution of PTP-OB as well as establishing a process for identifying compounds which modulate PTP-OB activity. Isolated and purified PTP-OB DNA would also be useful for the recombinant production of large quantities of PTP-OB protein. The ability to produce large quantities of the protein would be useful for the production of a therapeutic agent comprising PTP-OB protein. A therapeutic agent comprised of PTP-OB protein would be useful in the treatment of PTP-OB-related diseases or conditions which are PTP-OB responsive. By molecular cloning and DNA sequencing a new member of the protein tyrosine phosphates gene family, termed PTP-OB, was identified. PTP-OB has a receptor like structure and has the characteristic cytoplasmic protein tyrosine phosphatase region. The protein is composed of 1912 amino acid residues and shares similarities to the tyrosine phosphatases LAR, PTPδ and other known LAR related PTPases. Sequence analysis revealed two highly hydrophobic regions in PTP-OB protein. One, located at the amino terminus end, is likely to be the signal peptide. The second highly hydrophobic segment that is followed by positively charged residues is likely to serve as a transmembrane domain. In the cytoplasmic region, PTP-OB contains two tandem PTPase-like domains that are found in PTPase family. Sequence comparison with the known PTPases demonstrated that PTP- OB is homologues to LAR and PTPδ (Streuli, M. et al, 1988, J.Exp.Med., 168, pp.1523- 1530; Krueger, N.X. et al, 1990, EMBO J., 9, pp.3241-3252). The overall amino acid sequence homology approaches 68% and 59% respectively. Although the primary amino acid of extracellular regions diverged from that of LAR, the extracellular region of PTP-OB was observed to contain the three Ig-like domains and eight fibronectin type-in like domains that were found in LAR (Streuli, M. supra). Northern hybridization experiments with RNA from various cell and tissues indicated that both PTP-OB and PTPδ were expressed in bone and brain derived cells or tissues. Relatively high levels of PTP-OB and PTPδ transcripts were found in RNA isolated from human osteosarcoma tumor, human giant cell tumor, rat tibia and in relatively mature cultured osteoblasts isolated from mouse calvaria. Since osteosarcoma tumor is abundant with osteoblastic cells, and giant cell tumor is a mixed cell population of multinucleated osteoclast-like cells and osteoblastic cells and other non defined cells, it is likely that in bone, the osteoblastic cells were the source of PTP-OB and PTPδ RNA. In addition to the expression in bone RNA encoding PTP-OB and PTPδ were found in human brain as well in RNA isolated from the human glioblastoma tumor cell line U340. Overall, the expression of PTP-OB was more restricted to brain or bone derived cells and tissues than that of PTPδ. In addition to the expression in brain and bone, low levels of PTPδ were found in RNA isolated from lung, liver, kidney and pancreas. Although the complete sequence of PTPδ is not known, from the available sequences, it appeared to be structurally related to LAR and to PTP-OB. Studies with the similar PTPases in drosophila, suggested that these receptor-like PTPases that share structural features with cell adhesion molecules are involved with cell to cell or cell to matrix interactions. For both brain and bone, cell to cell or cell to matrix contacts are continually modified in an ongoing process. In bone, these receptor-like PTPases, may regulate the interaction of osteoblasts with each other or with the bone matrix. Experiments with cultured osteoblats, showed that vanadate, a PTPase inhibitor, stimulated cell proliferation and the synthesis of bone collagen (Lau et aL supra). These findings, suggest that these PTPases may play an important function in osteoblasts and their exact functions are yet to be determined. The following examples are provided as illustrative of the present invention without, however, limiting the same thereto. EXAMPLE 1 Primers Design Degenerate DNA primers were designed to recognize the coding region of the conserved amino acid residues of a typical protein tyrosine phosphatase domain. The sense primer, PH4, was the degenerate oligomer, 5' CTTCTAGAA(A/G)TG(T/C)GC(G/T/C/A)CA(A/G)TA(T/C)TGGCC (SEQ.ID.NO.: 1), that was prepared according to the conserved amino acid residues KCAQYWP (SEQ.ID.NO.: 2). The antisense primer, PH2a, 5'. GAAGCTTCC(C/A)A(CAT)(G/C T/A/)CCTGCAC(T/A)(A/G)CA(G/A) TG(C/G/T/A)AC 9 (SEQ.ID.NO.: 3), was designed to complement the DNA sequences coding for the amino acid residues VHCS A(V/I)G (SEQ.ID.NO.: 4) of the tyrosine phosphatase domain. cDNA Amplification Single stranded randomly primed cDNA was prepared with the Mo-MLV reverse transcriptase (BRL) from RNA isolated from a human osteosarcoma Saos-2/B 10 cells (Rodan et al 1987, 1989). The cDNA reaction (25 μl) was diluted into 300 μl water and heat denatured at 95°C for 5 minutes and quickly chilled on ice. The cDNA (5 μl) and the above primer pair, PH2a and PH4 (0.5 μM each) were employed in the amplification reaction with the Amplitaq kit and the DNA thermal cycler (Perkin Elmer, Cetus). The amplification cycles were as follows: denaturation at 94°C, 70 seconds; annealing at 50°C for 135 seconds; 3 minutes of gradual increase of the temperature to 72°C; extension at 72°C, 4 minutes for 40 cycles. The amplified fragments were separated by electrophoresis on 5% poly acrylamide gel, cloned into plasmids and sequenced. The cDNA clones were than used to screen lamda gtl 1 cDNA libraries and positive clones were isolated and their two DNA strands were sequenced. Screening of cDNA Libraries The cDNA libraries of human fetal lungs that were prepared from a mixture of 19-week and 21 -week-old fetuses and the human fetal brain of a 26- week-old male fetus were purchased (Clontech, CA). The human giant cell tumor and the human U340 brain tumor cell cDNA libraries were constructed in lamda gtl 1 by using a mixture of oligo dT and random primers (Super Script Choice System, BRL, MD). The cDNA libraries were plated at a density of 30,000 plaques per 150-mm plate and transferred to nylon filters (Hybond N, Amersham). A half or one million of recombinants of each library were screened using 32P- labeled probe. Positive plaques were identified and selected clones were insert into plasmids and sequences. Cloning of PTP-OB cDNA The polymerase chain reaction (PCR) strategy was employed in order to identify the PTPases that are expressed in bone- derived cells. Total RNA was isolated from human osteosarcoma SAOS- 2/B 10 cells after six hours treatment with TPA or control solution. The cDNA was prepared and subjected to PCR amplification with DNA primers that were synthesized according to the conserved amino acid residues of the tyrosine phosphatase domain found in the members of the PTP family. After separation of the amplification products on 5% polyacrylamide gel, multiple DNA fragments, with the size range of 290-315 bp, were observed with the reaction that contained the cDNA of the TPA treated cells. No detectable hybridizing DNA fragments were observed when the cDNA from the control cells was used as template. The DNA fragments were cloned into plasmid vectors and sequenced in their entirety. After sequence analysis, we found that the various cDNA clones represented DNA fragments of five different PTPases. Four of these PTPases were the known PTPδ (Krueger et al, supra), PTPgamma (Sap et ai, 1990, Proc.Natl.Acad.Sci. USA, 87, pp.61 12-61 16; Kaplan et al-, supra,), PTPalpha (Matthews et al-, 1990, Proc.Natl.Acad.Sci. USA, 89, pp-2980-2984; Kaplan et al-, supra), and PTP MEG (Gu, M. et al, 1992, Proc.Natl.Acad.Sci. USA, 89, pp.2980-2984). The fifth clone, named PTP-OB, is a novel, yet unreported, PTPase gene product. To obtain a complete cDNA sequence for the human PTP- OB, several cDNA libraries were screened which were either purchased or prepared according to standard methods. From a human fetal lung library, three cDNA clones were obtained that hybridized with the amplified 283 bp DNA fragment of PTP-OB. Analysis of the DNA sequence revealed that these three clones were identical and their sequences matched that of PTP-OB. Complete DNA sequencing of clone PTP-OB-17, revealed a 1714 bp cDNA that contained an open reading frame coding for a PTP like protein that was interrupted by a putative termination codon (Figure 1). To find additional cDNA sequences, we screened the cDNA library of the giant cell tumor with the cDNA of PTP-OB- 17. Seven cDNA clones were identified and the longest cDNA, PTP-OB- 10, was analyzed. Sequence analysis revealed a 3613 bp open reading frame that encodes for 1204 amino acid residues (Figure 1). Since the expression of PTP-OB was found in brain tissue a human brain cDNA library was screened with the 350 bp DNA fragment that corresponded to the most 5' end of clone PTP-OB- 10. Sixty positive clones were identified and after size selection and partial sequencing of several lambda clones, a clone of 3588 bp was identified, PTP-OB- 133, that contained an open reading frame that starts with the putative initiation codon at the 5' end. Overall, analysis of the assembled cDNA sequences revealed a cDNA of 5988 nucleotides (Figure 2) that contained a long open reading frame of 5733 bp that codes for 191 1 amino acid residues (Figure 3). At the 5' end of the cDNA three initiation codons were identified. The first methionine codon is the most suitable translation start site. A comparison of PTP- OB protein the known PTPases showed that it is most similar to PTPases LAR and LAR related PTPases . The amino acid sequence of PTP-OB showed 68% identity with LAR and 59% with PTPδ. Similar to LAR, PTP-OB has a receptor-like structure. A highly hydrophobic region is located next to the putative initiation codon, and is probably the signal peptide. According to the consensus rules for signal peptide cleavage, the thirtieth amino acid residue is probably the first amino acid of the mature protein. A second highly hydrophobic domain is found between amino acid residues 1253 to 1277 and is most likely to function as the transmembrane domain. Similar to observations for LAR, analysis of the primary amino acid sequence of the putative extracellular region indicated three repeats of immunoglobulin-like domains and eight fibronectin type Ill-like repeats (Streuli et al 1998). According to the consensus glycosilation sites, three potential N-linked glycosylation sites at position 250, 721 and 919 were identified. The extracellular domain of PTP-OB is 58% identical to the parallel domain of LAR and 40% identical to DLAR and is closely related to other LAR related PTPase proteins. The cytoplasmic domain of PTP-OB is composed of 626 amino acid residues. In this region the two tandem repeats of protein tyrosine phosphatase domains are recognized. The cytoplasmic region is highly conserved and it is 95% and 87% identical to the parallel domains of LAR and PTPδ respectively. Comparing the overlapping sequences of PTP-OB- 10 and PTP-OB- 133 revealed that the clone isolated from the brain library contained a deletion of 1225 nucleotides, between 1828 -3055 of the complete sequence, that maintained the open reading frame. Partial analysis of several other clones obtained from the brain library, revealed that they all had similar deletions thus coding for a protein with an extracellular domain that is shorter by 409 amino acid residues (between residues 604-1013) and with a substitution of a valine residue, V1014, to an isoleucine residue, il014. EXAMPLE 2 Tissue Distribution Of PTP-OB Expression RNA Hybridization RNA was isolated by the modified guanidinium hydrochloride method or by guanidinium isothiocyanate method (1 1.12). Total RNA (20-30 μg) and polyA selected RNA (2-5 μg) were separated on formaldehyde agarose gels and transferred nylon filters and subjected to hybridization with (Hybond N, Amersham). A northern blot of polyA+ RNA of various human tissues was purchased from Clontech, CA. The hybridization solutions contained 40-50% formamide (Hybrisol I and II, Oncor). After hybridization, the filters were washed in a solution of 2xSSC containing 0.1 % SDS, and finally in 0.2xSSC/0.1 % SDS solution at 55°C, and exposed to X-ray film (XAR-2, Kodak) with intensifying screen at -70°C for up to 10 days. Expression of PTP-OB mRNA PTP-OB cDNA was hybridized to RNA isolated form various cells and tissues. Northern hybridization experiments revealed that mRNA for PTP-OB is approximately 7.3 Kb. High steady state levels of PTP-OB RNA were found in human osteosarcoma tumor, giant cell tumor (GCT), and in mRNA prepared from human brain (Figures 4 and 5). In rat tissues, high level of expression of PTP-OB RNA was found in RNA prepared from tibia. Very low expression levels were detected in RNA isolated form lungs of one week old rat. Hybridization experiments with the cDNA for PTPδ, showed tissue distribution that was comparable to PTP-OB. PTPδ was found to be highly expressed in brain. Lower levels of PTPδ transcripts were found in RNA isolated from lung and very low but detectable levels were observed in liver, kidney and pancreas. In bone derived cells, high expression levels of PTPδ was found in the human osteosarcoma tumor, and human giant cell tumor (Figure 6). In cultured cells, there were high expression levels of both PTP-OB and PTPδ in osteoblasts isolated from mouse calvaria and in the human glioblastoma brain tumor U340. EXAMPLE 3 Cloning of the PTP-OB cDNA into E. coli Expression Vectors Recombinant PTP-OB is produced in E. coli following the transfer of the PTP-OB encoding DNA into E. coli expression vectors, including but not limited to, the pET series (Novagen). The pET vectors place PTP-OB expression under control of the tightly regulated bacteriophage T7 promoter. Following transfer of this construct into an E. coli host which contains a chromosomal copy of the T7 RNA polymerase gene driven by the inducible lac promoter, expression of PTP-OB is induced when an appropriate lac substrate (IPTG) is added to the culture. The levels of expressed PTP-OB are determined by the assays described above. The cDNA encoding the entire open reading frame for PTP- OB is inserted into the Ndel site of pET 11a. Constructs in the positive orientation are identified by sequence analysis and used to transform the expression host strain BL21. Transformants are then used to inoculate cultures for the production of PTP-OB protein. Cultures may be grown in M9 or ZB media, whose formulation is known to those skilled in the art. After growth to an approximate OD600= 1.5, expression of PTP-OB is induced with 1 mM IPTG for 3 hours at 37°C. Authentic PTP-OB may be found in the insoluble inclusion body fraction from these cells. Soluble PTP-OB is extracted from the inclusion body fraction with 5 M guanidine-HCl in a buffer containing 50 mM Tris-HCl (pH 8) and 100 mM dithiothreitol. Active PTP-OB is generated from this extract following dialysis against 100 volumes of 25 mM HEPES (pH 7.5), 5 mM dithiothreitol, 10% sucrose. EXAMPLE 4 In Vitro Translation of PTP-OB mRNA and Xenopus Oocyte Expression PTP-OB cDNA constructs are ligated into in vitro transcription vectors (the pGEM series, Promega) for the production of synthetic mRNAs. Synthetic mRNA is produced in sufficient quantity in vitro by cloning double stranded DNA encoding PTP-OB mRNA into a plasmid vector containing a bacteriophage promoter, linearizing the plasmid vector containing the cloned PTP-OB- encoding DNA, and transcribing the cloned DNA in vitro using a DNA-dependent RNA polymerase from a bacteriophage that specifically recognizes the bacteriophage promoter on the plasmid vector. Various plasmid vectors are available containing a bacteriophage promoter recognized by a bacteriophage DNA- dependent RNA polymerase, including but not limited to plasmids pSP64, pSP65, pSP70, pSP71 , pSP72, pSP73, pGEM-3Z, pGEM- 4Z, pGEM-3Zf, pGEM-5Zf, pGEM-7Zf , pGEM-9Zf, and pGEM- 1 lZf, the entire series of plasmids is commercially available from Promega. The double stranded PTP-OB-encoding DNA is cloned into the bacteriophage promoter containing vector in the proper orientation using one or more of the available restriction endonuclease cloning sites on the vector which are convenient and appropriate for cloning PTP-OB DNA. The vector with the ligated PTP-OB DNA is used to transform bacteria, and clonal isolates are analyzed for the presence of the vector with the PTP-OB DNA in the proper orientation. Once a vector containing the PTP-OB-encoding DNA in the proper orientation is identified and isolated, it is linearized by cleavage with a restriction endonuclease at a site downstream from, and without disrupting, the PTP-OB transcription unit. The linearized plasmid is isolated and purified, and used as a template for in vitro transcription of PTP-OB mRNA. The template DNA is then mixed with bacteriophage- specific DNA-dependent RNA polymerase in a reaction mixture which allows transcription of the DNA template forming PTP-OB mRNA. Several bacteriophage-specific DNA-dependent RNA polymerases are available, including but not limited to T3, T7, and SP6 RNA polymerase. The synthetic PTP-OB mRNA is then isolated and purified. It may be advantageous to synthesize mRNA containing a 5' terminal cap structure and a 3' poly A tail to improve mRNA stability. A cap structure, or 7-methylguanosine, may be incorporated at the 5'terminus of the mRNA by simply adding 7-methylguanosine to the reaction mixture with the DNA template. The DNA-dependent RNA polymerase incorporates the cap structure at the 5' terminus as it synthesizes the mRNA. The poly A tail is found naturally occurring in many cDNAs but can be added to the 3' terminus of the mRNA by simply inserting a poly A tail-encoding DNA sequence at the 3' end of the DNA template. The isolated and purified PTP-OB mRNA is translated using either a cell-free system, including but not limited to rabbit reticulocyte lysate and wheat germ extracts (both commercially available from Promega and New England Nuclear) or in a cell based system, including but not limited to microinjection into Xenopus oocytes, with microinjection into Xenopus oocytes being preferred. Xenopus oocytes are microinjected with a sufficient amount of synthetic PTP-OB mRNA to produce PTP-OB protein. The microinjected oocytes are incubated to allow translation of the PTP-OB mRNA, forming PTP-OB protein. These synthetic mRNAs are injected into Xenopus oocytes (stage 5 -6) by standard procedures [Gurdon, J.B. and Wickens, M.D. Methods in Enzymol. 101: 370-386, (1983)]. Oocytes are harvested and analyzed for PTP-OB expression . EXAMPLE 6 Cloning of PTP-OB cDNA into a Mammalian Expression Vector PTP-OB cDNA expression cassettes are ligated at appropriate restriction endonuclease sites to the following vectors containing strong, universal mammalian promoters: pBC12BI [Cullen, B.R. Methods in Enzymol. 152: 684-704 1988], and pEE12 (CellTech EP O 338,841) and its derivatives pSZ9016-l and p9019. p9019 represents the construction of a mammalian expression vector containing the hCMVIE promoter, polylinker and SV40 polyA element with a selectable marker/amplification system comprised of a mutant gene for dihydrofolate reductase (mDHFR) (Simonsen, C.C. and Levinson, A. D. Proc. Natl. Acad. Sci US A 80: 2495-2499 [1983]) driven by the S V40 early promoter. An SV40 polyadenylation sequence is generated by a PCR reaction defined by primers 13978-120 and 139778-121 using pD5 (Berker and Sharp, Nucl. Acid Res. 13: 841-857 [1985]) as template. The resulting 0.25 Kb PCR product is digested with Clal and Spel and ligated into the 6.7 Kb fragment of pEE12 which had been likewise digested. The resultant plasmid is digested with Bglll and Sfil to liberate the 3' portion of the S V40 early promoter and the GScDNA from the vector. A 0.73 Kb Sfil-XhoII fragment isolated from plasmid pFR400 (Simonsen, C.C. and Levinson, A. D. Proc. Natl. Acad. Sci USA 80: 2495-2499 [1983]) is ligated to the 5.6 Kb vector described above, reconstituting the SV40 early promoter, and inserting the mdHFR gene. This plasmid is designated p9019. ρSZ9016-l is identical to p9019 except for the substitution of the HIV LTR for the huCMVIE promoter. This vector is constructed by digesting p9019 with Xbal and Mlul to remove the huCMVIE promoter. The HIV LTR promoter, from residue -1 17 to +80 (as found in the vector pCD23 containing the portion of the HIV-1 LTR (Cullen, Cell 46:973 [1986]) is PCR amplified from the plasmid pCD23 using oligonucleotide primers which appended to the ends of the product the Mlul and Spel restriction sites on the 5' side while Hind IH and Xba I sites are appended on the 3' side. Following the digestion of the resulting 0.2 kb PCR product with the enzymes Mlul and Xba I the fragment is agarose gel-purified and ligated into the 4.3 Kb promoterless DNA fragment to generate the vector pSZ9016-l . Cassettes containing the PTP-OB cDNA in the positive orientation with respect to the promoter are ligated into appropriate restriction sites 3' of the promoter and identified by restriction site mapping and/or sequencing. These cDNA expression vectors are introduced into various host cells including, but not limited to: [COS-7 (ATCC# CRL1651), CV-1 tat [Sackevitz et al., Science 238: 1575 (1987)], 293, L (ATCC# CRL6362)] by standard methods including but not limited to electroporation,or chemical procedures (cationic liposomes, DEAE dextran, calcium phosphate). Transfected cells and cell culture extracts can be harvested and analyzed for PTP-OB expression as described below. All of the vectors used for mammalian transient expression can be used to establish stable cell lines expressing PTP-OB. Unaltered PTP-OB cDNA constructs cloned into expression vectors will be expected to program host cells to make intracellular PTP-OB protein. The transfection host cells include, but are not limited to, CV-l-P [Sackevitz et al., Science 238: 1575 (1987)], tk-L [Wigler, et al. Cell 1 1 : 223 (1977)], NS/0, and dHFr- CHO [Kaufman and Sharp, J. Mol. Biol. 159: 601 , (1982)]. Co-transfection of any vector containing PTP-OB cDNA with a drug selection plasmid including, but not limited to G418, aminoglycoside phosphotransf erase, pLNCX [Miller, A.D. and Rosman G. J. Biotech News 7: 980-990 (1989)]; hygromycin, hygromycin-B phosphotransferase, pLG90 [Gritz. L. and Davies, J., GENE 25: 179 (1983)] ; APRT, xanthine-guanine phosphoribosyl-transferase, pMAM (Clontech) [Murray, et al., Gene 31 : 233 (1984)] will allow for the selection of stably transfected clones. Levels of PTP-OB are quantitated by the assays described above. PTP-OB cDNA constructs are ligated into vectors containing amplifiable drug-resistance markers for the production of mammalian cell clones synthesizing the highest possible levels of PTP-OB. Following introduction of these constructs into cells, clones containing the plasmid are selected with the appropriate agent, and isolation of an over-expressing clone with a high copy number of the plasmid is accomplished by selection in increasing doses of the agent. The following systems are utilized: the 9016 or the 9019 plasmid containing the mutant DHFR gene [Simonson, C. and Levinson, A., Proc. Natl. Acad. Sci. USA 80: 2495 (1983)], transfected into DHFR- CHO cells and selected in methotrexate; the pEE12 plasmid containing the glutamine synthetase gene, transfected into NS/O cells and selected in methionine sulfoximine (CellTech Intemational Patent Application 2089/10404); and 9016 or other CMV promoter vectors, co- transfected with pDLAT-3 containing the thymidine kinase gene [Colbere and Garopin, F., Proc. Natl. Acad. Sci. 76: 3755 (1979)] in APRT and TK deficient L cells, selected in APRT (0.05 mM azaserine, 0.1 mM adenine, 4 ug/ml adenosine) and amplified with HAT (100 uM hypoxanthine, 0.4 uM aminopterin, 16 uM thymidine). EXAMPLE 7 Cloning of PTP-OB cDNA into a Baculovirus Expression Vector for Expression in Insect Cells Baculovirus vectors, which are derived from the genome of the AcNPV virus, are designed to provide high level expression of cDNA in the Sf9 line of insect cells (ATCC CRL# 171 1 ). Recombinant baculoviruses expressing PTP-OB cDNA is produced by the following standard methods (InVitrogen Maxbac Manual): the PTP-OB cDNA constructs are ligated downstream of the polyhedrin promoter in a variety of baculovirus transfer vectors, including the pAC360 and the BlueBac vector (InVitrogen). Recombinant baculo viruses are generated by homologous recombination following co-transfection of the baculovirus transfer vector and linearized AcNPV genomic DNA [Kitts, P.A., Nuc. Acid. Res. 18: 5667 (1990)] into Sf9 cells. Recombinant pAC360 viruses are identified by the absence of inclusion bodies in infected cells (Summers, M. D. and Smith, G. E., Texas Agriculture Exp. Station Bulletin No. 1555) and recombinant pBlueBac viruses are identified on the basis of β- galactosidase expression (Vialard, et al. 1990, J. Virol., 64, PP 37- 50). Following plaque purification and infection of sf9 cells with PTP-OB recombinant baculovirus, PTP-OB expression is measured by the assays described above. The cDNA encoding the entire open reading frame for PTP-OB is inserted into the BamHI site of pBlueBacD Constructs in the positive orientation with respect to the polyhedrin promoter are identified by sequence analysis and used to transfect Sf9 cells in the presence of linear AcNPV mild type DNA. EXAMPLE 8 Cloning of PTP-OB cDNA into a Yeast Expression Vector Recombinant PTP-OB is produced in the yeast S cerevisiae following the insertion of the optimal PTP-OB cDNA construct into expression vectors designed to direct the intracellular expression of heterologous proteins. For intracellular expression, vectors such as EmBLyex4 or the like are ligated to the PTP-OB cistron [Rinas, U. et al, Biotechnology 8: 543-545 (1990); Horowitz B. et al., J. Biol. Chem. 265: 4189-4192 (1989)]. The levels of expressed PTP-OB are determined by the assays described above. EXAMPLE 9 Purification of Recombinant PTP-OB Recombinantly produced PTP-OB may be purified by antibody affinity chromatography. PTP-OB antibody affinity columns are made by adding the anti-PTP-OB antibodies to Affigel-10 (Biorad), a gel support which is pre-activated with N-hydroxysuccinimide esters such that the antibodies form covalent linkages with the agarose gel bead support. The antibodies are then coupled to the gel via amide bonds with the spacer arm. The remaining activated esters are then quenched with 1M ethanolamine HC1 (pH 8). The column is washed with water followed by 0.23 M glycine HC1 (pH 2.6) to remove any non-conjugated antibody or extraneous protein. The column is then equilibrated in phosphate buffered saline (pH 7.3) together with appropriate membrane solubilizing agents, if necessary such as detergents, and the cell culture supematants or cell extracts containing PTP-OB or PTP-OB fragments are slowly passed through the column. The column is then washed with phosphate- buffered saline together with detergents, if necessary until the optical density (A280) falls to background, then the protein is eluted with 0.23 M glycine-HCl (pH 2.6) together with detergents, if necessary. The purified PTP-OB protein is then dialyzed against phosphate buffered saline. EXAMPLE 10 Screening Assay to Identify Modulators of PTP Activity Mouse osteoclasts were generated in vitro by culturing together bone marrow cells and calvariae osteoblasts as previously described (Tanaka et al.). Osteoblastic cells were isolated from mouse calvariae and cultured for 24 hours. Then, freshly isolated bone marrow cells were added to the cultured osteoblasts and treated with 10 nM l,25(OH)2D3 (D3) for seven days. Under these conditions the bone marrow cells differentiated into multinucleated osteoclast-like cells that were positively stained for tartarat resistant alkaline phosphatase (TRAP) and other osteoclast specific markers (Takahashi, N.T. et al-, 1988, Endocrinol., 123, pp.2600-2602). The D3 and the various inhibitors were added to the cells with fresh medium at days two and four of co- culturing. Mouse bone marrow cells, were induced to differentiate into osteoclast-like cells by co-culturing with neonatal calvariae osteoblasts in a D3 dependent process. These cells were stained by tartarat resistant acid phosphatase and exhibited markers that were associated with osteoclasts, such as calcitonin receptors, and vitronectin receptors. Furthermore, like osteoclasts, the cells contained multiple nuclei as a result of cell fusion activities ( Takahashi, N.T. et al., supra). The multinucleated TRAP positive cells could be recognized as early as four days of co-culturing, but the majority of the multinucleated osteoclast- like cells (70-80%) were generated after six and seven days of co- culturing. The process was completely dependent on the treatment with vitamin D3, and no osteoclasts were formed in the absence of either D3, osteoblasts or bone marrow cells ( Takahashi, N.T. et al., supra ). To test for the importance of PTPase activity in the generation of osteoclasts, we studied the influence of PTPase inhibitors on the differentiation of bone marrow cells in osteoclast. In these experiments, addition of orthovanadate to the co-cultured cells completely inhibited the formation of the multinucleated TRAP positive cells, with an IC 50 of 2 μM (Figure 7). Similarly, treatment with phenylarsine oxide (PAO) strongly inhibited the formation of the multinucleated TRAP positive cells with an IC 50 of 0.2 μM (Figure 7). Treatment with orthovanadate (lOμM) or phenylarsine oxide (0.2μM), which markedly inhibited the formation of the fused TRAP positive cells, produced mononucleated TRAP positive cells. Thus, the major influence of the inhibitors appeared to be on the process of cell fusion. Moreover, at these concentration of PFPase inhibitors, no ill effects were observed on the co-cultured osteoblasts. To further characterize the importance of the PTPases on osteoclast formation, orthovanadate was added at different days of co-culturing and the formation of fused TRAP positive cells was measured. In these experiments the orthovanadate was able to block 80% of the formation of the multinucleated TRAP positive cells when added at six days of co-culturing (Figure 8). Addition of the PTPase inhibitor at earlier days of the co-culturing before the major cell fusion occuned had a small additional effect. To further study the role of tryosine phosphorylation in osteoclast formation, influence of geldanamycin, a tyrosine kinase inhibitor, on the formation of osteoclasts was tested. In these experiments, geldanamycin was a potent inhibitor of osteoclasts formation, with an IC 50 of 50ng/ml (Figure 7). Though, in contrast to the PTPase inhibitors, it completely blocked the appearance of mononuclear trap positive cells. To test whether PTPase activity could influence the osteoclasts activity, the influence of the PTPase inhibitors was tested in an in vitro bone resorption assay. In these assays, freshly isolated rat osteoclasts were placed on bone slices for 24 hours and the influence of PTPase inhibitors on the number of resorbing pits in the bone slice were observed. Both orthovanadate and phenylarsine oxide were found to be potent inhibitors of bone resorption (Figure 9), with an IC50 of 2μM for orthovanadate and IC 50 of 0.05 μM for penylarsine oxide. EXAMPLE 11 Recombinant protein tyrosine phosphatase PTP-OB is expressed in a recombinant host cell (as in Examples 1-10) in native form or as a hybrid or fusion protein. PTP-OB is then used in an enzymatic assay for tyrosine phosphatase activity in a suitable buffer (0.1M TRIS- HCL, pH 7.4; ImM EDTA; 50mM NaCl; ImM DTT). As a substrate, a phosphorylated peptide or protein is added as well as phosphorylated tyrosine or similar molecule. The release of phosphate is measured by colorimetric assay or by the release of radiolabelled phosphate. Various inhibitors are addad to the assay reaction to determine their inhibitory effect on the enzymatic activity of PTP-OB. The potential inhibitor substances for use in this assay are produced synthetically or are isolated from natural sources. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: RODAN, GIDEON A SCHMIDT, AZRIEL RUTLEDGE, SU JANE (ii) TITLE OF INVENTION: CDNA ENCODING A NOVEL HUMAN PROTEIN TYROSINE PHOSPHATASE (iii) NUMBER OF SEQUENCES: 6 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: JOHN W. WALLEN III (B) STREET: P.O. BOX 2000, 126 E. LINCOLN AVE. (C) CITY: RAHWAY (D) STATE: NJ (E) COUNTRY: USA (F) ZIP: 07065 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: US 08/122,032 (B) FILING DATE: 14-SEP-1993 (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: WALLEN, JOHN W III (B) REGISTRATION NUMBER: 35403 (C) REFERENCE/DOCKET NUMBER: 18992 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 908-594-3905 (B) TELEFAX: 908-594-4720 (C) TELEX: 138825 (2) INFORMATION FOR SEQ ID NO:1 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: CTTCTAGAAR TGYGCNCART AYTGGCC 27 (2) INFORMATION FOR SEQ ID NO:2 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2 : Lys Cys Ala Gin Tyr Trp Pro 1 5 (2) INFORMATION FOR SEQ ID NO:3 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3 : GAAGCTTCCM AYNCCTGCAC WRCARTGNAC 30 (2) INFORMATION FOR SEQ ID NO:4 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Val His Cys Ser Ala Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 5 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1911 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: Met Ala Pro Thr Trp Gly Pro Gly Met Val Ser Val Val Gly Pro Met 1 5 10 15 Gly Leu Leu Val Val Leu Leu Val Gly Gly Cys Ala Ala Glu Glu Pro 20 25 30 Pro Arg Phe lie Lys Glu Pro Lys Asp Gin lie Gly Val Ser Gly Arg 35 40 45 Val Ala Ser Phe Val Cys Gin Ala Thr Gly Asp Pro Lys Pro Arg Val 50 55 60 Thr Trp Asn Lys Lys Gly Lys Lys Val Asn Ser Gin Arg Phe Glu Thr 65 70 75 80 lie Glu Phe Asp Glu Ser Ala Gly Ala Val Leu Arg lie Gin Pro Leu 85 90 95 Arg Thr Pro Arg Asp Glu Asn Val Tyr Glu Cys Val Ala Gin Asn Ser 100 105 110 Val Gly Glu lie Thr Val His Ala Lys Leu Thr Val Leu Arg Glu Asp 115 120 125 Gin Leu Pro Ser Gly Phe Pro Asn lie Asp Met Gly Pro Gin Leu Lys 130 135 140 Val Val Glu Arg Thr Arg Thr Ala Thr Met Leu Cys Ala Ala Ser Gly 145 150 155 160 Asn Pro Asp Pro Glu lie Thr Trp Phe Lys Asp Phe Leu Pro Val Asp 165 170 175 Pro Ser Ala Ser Asn Gly Arg lie Lys Gin Leu Arg Ser Gly Ala Leu 180 185 190 Gin lie Glu Ser Ser Glu Glu Thr Asp Gin Gly Lys Tyr Glu Cys Val 195 200 205 Ala Thr Asn Ser Ala Gly Val Arg Tyr Ser Ser Pro Ala Asn Leu Tyr 210 215 220 Val Arg Val Arg Arg Val Ala Pro Arg Phe Ser lie Leu Pro Met Ser 225 230 235 240 His Glu He Met Pro Gly Gly Asn Val Asn He Thr Cys Val Ala Val 245 250 255 Gly Ser Pro Met Pro Tyr Val Lys Trp Met Gin Gly Ala Glu Asp Leu 260 265 270 Thr Pro Glu Asp Asp Met Pro Val Gly Arg Asn Val Leu Glu Leu Thr 275 280 285 Asp Val Lys Asp Ser Ala Asn Tyr His Pro Cys Val Ala Met Ser Ser 290 295 300 Leu Gly Val He Glu Ala Val Ala Gin He Thr Val Lys Ser Leu Pro 305 310 315 320 Lys Ala Pro Gly Thr Pro Met Val Thr Glu Asn Thr Ala Thr Ser He 325 330 335 Thr He Thr Trp Asp Ser Gly Asn Pro Asp Pro Val Ser Tyr Tyr Val 340 345 350 He Glu Tyr Lys Ser Lys Ser Gin Asp Gly Pro Tyr Gin He Lys Glu 355 360 365 Asp He Thr Thr Thr Arg Tyr Ser He Gly Gly Leu Ser Pro Asn Ser 370 375 380 Glu Tyr Glu He Trp Val Ser Ala Val Asn Ser He Gly Gin Gly Pro 385 390 395 400 Pro Ser Glu Ser Val Val Thr Arg Thr Gly Glu Gin Ala Pro Ala Arg 405 410 415 Pro Pro Arg Asn Val Gin Ala Arg Met Leu Ser Ala Thr Thr Met He 420 425 430 Val Gin Trp Glu Glu Pro Val Glu Pro Asn Gly Leu He Arg Gly Tyr 435 440 445 Arg Val Tyr Tyr Thr Met Glu Pro Glu His Pro Val Gly Asn Trp Gin 450 455 460 Lys His Asn Val Asp Asp Ser Leu Leu Thr Thr Val Gly Ser Leu Leu 465 470 475 480 Glu Asp Glu Thr Tyr Thr Val Arg Val Leu Ala Phe Thr Ser Val Gly 485 490 495 Asp Gly Pro Leu Ser Asp Pro He Gin Val Lys Thr Gin Gin Gly Val 500 505 510 Pro Gly Gin Pro Met Asn Leu Arg Ala Glu Ala Arg Ser Glu Thr Ser 515 520 525 He Thr Leu Ser Trp Ser Pro Pro Arg Gin Glu Ser He He Lys Tyr 530 535 540 Glu Leu Leu Phe Arg Glu Gly Asp His Gly Arg Glu Val Gly Arg Thr 545 550 555 560 Phe Asp Pro Thr Thr Ser Tyr Val Val Glu Asp Leu Lys Pro Asn Thr 565 570 575 Glu Tyr Ala Phe Arg Leu Ala Ala Arg Ser Pro Gin Gly Leu Gly Ala 580 585 590 Phe Thr Pro Val Val Arg Gin Arg Thr Leu Gin Ser Lys Pro Ser Ala 595 600 605 Pro Pro Gin Asp Val Lys Cys Val Ser Val Arg Ser Thr Ala He Leu 610 615 620 Val Ser Trp Arg Pro Pro Pro Pro Glu Thr His Asn Gly Ala Leu Val 625 630 635 640 Gly Tyr Ser Val Arg Tyr Arg Pro Leu Gly Ser Glu Asp Pro Glu Pro 645 650 655 Lys Glu Val Asn Gly He Pro Pro Thr Thr Thr Gin He Leu Leu Glu 660 665 670 Ala Leu Glu Lys Trp Thr Gin Tyr Arg He Thr Thr Val Ala His Thr 675 680 685 Glu Val Gly Pro Gly Pro Glu Ser Ser Pro Val Val Val Arg Thr Asp 690 695 700 Glu Asp Val Pro Ser Ala Pro Pro Arg Lys Val Glu Ala Glu Ala Leu 705 710 715 720 Asn Ala Thr Ala He Arg Val Leu Trp Arg Ser Pro Ala Pro Gly Arg 725 730 735 Gin His Gly Gin He Arg Gly Tyr Gin Val His Tyr Val Arg Met Glu 740 745 750 Gly Ala Glu Ala Arg Gly Pro Pro Arg He Lys Asp Val Met Leu Ala 755 760 765 Asp Ala Gin Glu Met Val He Thr Asn Leu Gin Pro Glu Thr Ala Tyr 770 775 780 Ser He Thr Val Ala Ala Tyr Thr Met Lys Gly Asp Gly Ala Arg Ser 785 790 795 800 Lys Pro Lys Val Val Val Thr Lys Gly Ala Val Leu Gly Arg Pro Thr 805 810 815 Leu Ser Val Gin Gin Thr Pro Glu Gly Ser Leu Leu Ala Arg Trp Glu 820 825 830 Pro Pro Ala Gly Thr Ala Glu Asp Gin Val Leu Gly Tyr Arg Leu Gin 835 840 845 Phe Gly Arg Glu Asp Ser Thr Pro Leu Ala Thr Leu Glu Phe Pro Pro 850 855 860 Ser Glu Asp Arg Tyr Thr Ala Ser Gly Val His Lys Gly Ala Thr Tyr 865 870 875 880 Val Phe Arg Leu Ala Ala Arg Ser Pro Gly Gly Leu Gly Glu Glu Ala 885 890 895 Ala Glu Val Leu Ser He Pro Glu Asp Thr Pro Arg Gly His Pro Gin 900 905 910 He Leu Glu Ala Ala Gly Asn Ala Ser Ala Gly Thr Val Leu Leu Arg 915 920 925 Trp Leu Pro Pro Val Pro Ala Glu Arg Asn Gly Ala He Val Lys Tyr 930 935 940 Thr Val Ala Val Arg Glu Ala Gly Ala Leu Gly Pro Ala Arg Glu Thr 945 950 955 960 Glu Leu Pro Ala Gly Arg Leu Ser Arg Ala Arg Arg Thr Leu Thr Leu 965 970 975 Gin Gly Leu Lys Pro Asp Thr Ala Tyr Asp Leu Gin Val Arg Ala His 980 985 990 Thr Arg Arg Gly Pro Gly Pro Phe Ser Pro Pro Val Arg Tyr Arg Thr 995 1000 1005 Phe Leu Arg Asp Gin Val Ser Pro Lys Asn Phe Lys Val Lys Met He 1010 1015 1020 Met Lys Thr Ser Val Leu Leu Ser Trp Glu Phe Pro Asp Asn Tyr Asn 1025 1030 1035 1040 Ser Pro Thr Pro Tyr Lys He Gin Tyr Asn Gly Leu Thr Leu Asp Val 1045 1050 1055 Asp Gly Arg Thr Thr Lys Lys Leu He Thr His Leu Lys Pro His Thr 1060 1065 1070 Phe Tyr Asn Phe Val Leu Thr Asn Arg Gly Ser Ser Leu Gly Gly Leu 1075 1080 1085 Gin Gin Thr Val Thr Ala Trp Thr Ala Phe Asn Leu Leu Asn Gly Lys 1090 1095 1100 Pro Ser Val Ala Pro Lys Pro Asp Ala Asp Gly Phe He Met Val Tyr 1105 1110 1115 1120 Leu Pro Asp Gly Gin Ser Pro Val Pro Val Gin Ser Tyr Phe He Val 1125 1130 1135 Met Val Pro Leu Arg Lys Ser Arg Gly Gly Gin Phe Leu Thr Pro Leu 1140 1145 1150 Gly Ser Pro Glu Asp Met Asp Leu Glu Glu Leu He Gin Asp He Ser 1155 1160 1165 Arg Leu Gin Arg Arg Ser Leu Arg His Ser Arg Gin Leu Glu Val Pro 1170 1175 1180 Arg Pro Tyr He Ala Ala Arg Phe Ser Val Leu Pro Pro Thr Phe His 1185 1190 1195 1200 Pro Gly Asp Gin Lys Gin Tyr Gly Gly Phe Asp Asn Arg Gly Leu Glu 1205 1210 1215 Pro Gly His Arg Tyr Val Leu Phe Val Leu Ala Val Leu Gin Lys Ser 1220 1225 1230 Glu Pro Thr Phe Ala Ala Ser Pro Phe Ser Asp Pro Phe Gin Leu Asp 1235 1240 1245 Asn Pro Asp Pro Gin Pro He Val Asp Gly Glu Glu Gly Leu He Trp 1250 1255 1260 Val He Gly Pro Val Leu Ala Val Val Phe He He Cys He Val He 1265 1270 1275 1280 Ala He Leu Leu Tyr Lys Asn Lys Pro Asp Ser Lys Arg Lys Asp Ser 1285 1290 1295 Glu Pro Arg Thr Lys Cys Leu Leu Asn Asn Ala Asp Leu Ala Pro His 1300 1305 1310 His Pro Lys Asp Pro Val Glu Met Arg Arg He Asn Phe Gin Thr Pro 1315 1320 1325 Gly Met Leu Ser His Pro Pro He Pro He Ala Asp Met Ala Glu His 1330 1335 1340 Thr Glu Arg Leu Lys Ala Asn Asp Ser Leu Lys Leu Ser Gin Glu Tyr 1345 1350 1355 1360 Glu Ser He Asp Pro Gly Gin Gin Phe Thr Trp Glu His Ser Asn Leu 1365 1370 1375 Glu Val Asn Lys Pro Lys Asn Arg Tyr Ala Asn Val He Ala Tyr Asp 1380 1385 1390 His Ser Arg Val He Leu Gin Pro He Glu Gly He Met Gly Ser Asp 1395 1400 1405 Tyr He Asn Ala Asn Tyr Val Asp Gly Tyr Arg Arg Gin Asn Ala Tyr 1410 1415 1420 He Ala Thr Gin Gly Pro Leu Pro Glu Thr Phe Gly Asp Phe Trp Arg 1425 1430 1435 1440 Met Val Trp Glu Gin Arg Ser Ala Thr He Val Met Met Thr Arg Leu 1445 1450 1455 Glu Glu Lys Ser Arg He Lys Cys Asp Gin Tyr Trp Pro Asn Arg Gly 1460 1465 1470 Thr Glu Thr Tyr Gly Phe He Gin Val Thr Leu Leu Asp Thr He Glu 1475 1480 1485 Leu Ala Thr Phe Cys Val Arg Thr Phe Ser Leu His Lys Asn Gly Ser 1490 1495 1500 Ser Glu Lys Arg Glu Val Arg Gin Phe Gin Phe Thr Ala Trp Pro Asp 1505 1510 1515 1520 His Gly Val Pro Glu Tyr Pro Thr Pro Phe Leu Ala Phe Leu Arg Arg 1525 1530 1535 Val Lys Thr Cys Asn Pro Pro Asp Ala Gly Pro He Val Val His Cys 1540 1545 1550 Ser Ala Gly Val Gly Arg Thr Gly Cys Phe He Val He Asp Ala Met 1555 1560 1565 Leu Glu Arg He Lys Pro Glu Lys Thr Val Asp Val Tyr Gly His Val 1570 1575 1580 Thr Leu Met Arg Ser Gin Arg Asn Tyr Met Val Gin Thr Glu Asp Gin 1585 1590 1595 1600 Tyr Ser Phe He His Glu Ala Leu Leu Glu Ala Val Gly Cys Gly Asn 1605 1610 1615 Thr Glu Val Pro Ala Arg Ser Leu Tyr Ala Tyr He Gin Lys Leu Ala 1620 1625 1630 Gin Val Glu Pro Gly Glu His Val Thr Gly Met Glu Leu Glu Phe Lys 1635 1640 1645 Arg Leu Ala Asn Ser Lys Ala His Thr Ser Arg Phe He Ser Ala Asn 1650 1655 1660 Leu Pro Cys Lys Lys Phe Lys Asn Arg Leu Val Asn He Met Pro Tyr 1665 1670 1675 1680 Glu Ser Thr Arg Val Cys Leu Gin Pro He Arg Gly Val Glu Gly Ser 1685 1690 1695 Asp Tyr He Asn Ala Ser Phe He Asp Gly Tyr Arg Gin Gin Lys Ala 1700 1705 1710 Tyr He Ala Thr Gin Gly Pro Leu Ala Glu Thr Thr Glu Asp Phe Trp 1715 1720 1725 Arg Met Leu Trp Glu Asn Asn Ser Thr He Val Val Met Leu Thr Lys 1730 1735 1740 Leu Arg Glu Met Gly Arg Glu Lys Cys His Gin Tyr Trp Pro Ala Glu 1745 1750 1755 1760 Arg Ser Ala Arg Tyr Gin Tyr Phe Val Val Asp Pro Met Ala Glu Tyr 1765 1770 1775 Asn Met Pro Gin Tyr He Leu Arg Glu Phe Lys Val Thr Asp Ala Arg 1780 1785 1790 Asp Gly Gin Ser Arg Thr Val Arg Gin Phe Gin Phe Thr Asp Trp Pro 1795 1800 1805 Glu Gin Gly Val Pro Lys Ser Gly Glu Gly Phe He Asp Phe He Gly 1810 1815 1820 Gin Val His Lys Thr Lys Glu Gin Phe Gly Gin Asp Gly Pro He Ser 1825 1830 1835 1840 Val His Cys Ser Ala Gly Val Gly Arg Thr Gly Val Phe He Thr Leu 1845 1850 1855 Ser He Val Leu Glu Arg Met Arg Tyr Glu Gly Val Val Asp He Phe 1860 1865 1870 Gin Thr Val Lys Met Leu Arg Thr Gin Arg Pro Ala Met Val Gin Thr 1875 1880 1885 Glu Asp Glu Tyr Gin Phe Cys Tyr Gin Ala Ala Leu Glu Tyr Leu Gly 1890 1895 1900 Ser Phe Asp His Tyr Ala Thr 1905 1910 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6000 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: GAATTCCGGG TCGCTGCCAA GCATGGCGCC CACCTGGGGC CCTGGCATGG TGTCTGTGGT 60 TGGTCCCATG GGCCTCCTTG TGGTCCTGCT CGTTGGAGGC TGTGCAGCAG AAGAGCCCCC 120 CAGGTTTATC AAAGAACCCA AGGACCAGAT CGGCGTGTCG GGGCGTGTGG CCTCTTTCGT 180 GTGTCAGGCC ACGGGTGACC CCAAGCCACG AGTGACCTGG AACAAGAAGG GCAAGAAGGT 240 CAACTCTCAG CGCTTTGAGA CGATTGAGTT TGATGAGAGT GCAGGGGCAG TGCTGAGGAT 300 CCAGCCGCTG AGGACACCGC GGGATGAAAA CGTGTACGAG TGTGTGGCCC AGAACTCGGT 360 TGGGGAGATC ACAGTCCATG CCAAGCTTAC TGTCCTCCGA GAGGACCAGC TGCCCTCTGG 420 CTTCCCCAAC ATCGACATGG GCCCACAGTT GAAGGTGGTG GAGCGGACAC GGACAGCCAC 480 CATGCTCTGT GCAGCCAGCG GCAACCCTGA CCCTGAGATC ACCTGGTTCA AGGACTTCCT 540 GCCTGTGGAT CCTAGTGCCA GCAATGGACG CATCAAACAG CTGCGATCAG GAGCCCTGCA 600 GATTGAAAGC AGTGAGGAAA CCGACCAGGG CAAATATGAG TGTGTGGCCA CCAACAGCGC 660 CGGCGTGCGC TACTCCTCAC CTGCCAACCT CTACGTGCGA GTCCGCCGCG TGGCCCCGCG 720 CTTCTCCATC CTGCCCATGA GCCACGAGAT CATGCCAGGG GGCAACGTGA ACATCACCTG 780 CGTGGCCGTG GGCTCGCCCA TGCCATACGT GAAGTGGATG CAGGGGGCCG AGGACCTGAC 840 CCCCGAGGAT GACATGCCCG TGGGTCGGAA CGTGCTGGAA CTCACAGATG TCAAGGACTC 900 GGCCAACTAC CACCCCTGCG TGGCCATGTC CAGCCTGGGC GTCATTGAGG CGGTTGCTCA 960 GATCACGGTG AAATCTCTCC CCAAAGCTCC CGGGACTCCC ATGGTGACTG AGAACACAGC 1020 CACCAGCATC ACCATCACGT GGGACTCGGG CAACCCAGAT CCTGTGTCCT ATTACGTCAT 1080 CGAATATAAA TCCAAGAGCC AAGACGGGCC GTATCAGATT AAAGAGGACA TCACCACCAC 1140 ACGTTACAGC ATCGGCGGCC TGAGCCCCAA CTCGGAGTAC GAGATCTGGG TGTCGGCCGT 1200 CAACTCCATC GGCCAGGGGC CCCCCAGCGA GTCCGTGGTC ACCCGCACAG GCGAGCAGGC 1260 CCCGGCCAGG CCGCCGCGGA ACGTGCAAGC CCGGATGCTC AGCGCGACCA CCATGATTGT 1320 GCAGTGGGAG GAGCCGGTGG AGCCCAACGG CCTGATCCGC GGCTACCGCG TCTACTACAC 1380 CATGGAACCG GAGCACCCCG TGGGCAACTG GCAGAAGCAC AACGTGGACG ACAGCCTGCT 1440 GACCACCGTG GGCAGCCTGC TGGAGGACGA GACCTACACC GTGCGGGTGC TCGCCTTCAC 1500 CTCCGTCGGC GACGGGCCCC TCTCGGACCC CATCCAGGTC AAGACGCAGC AGGGAGTGCC 1560 GGGCCAGCCC ATGAACCTGC GGGCCGAGGC CAGGTCGGAG ACCAGCATCA CGCTGTCCTG 1620 GAGCCCCCCG CGGCAGGAGA GTATCATCAA GTACGAGCTC CTCTTCCGGG AAGGCGACCA 1680 TGGCCGGGAG GTGGGAAGGA CCTTCGACCC GACGACTTCC TACGTGGTGG AGGACCTGAA 1740 GCCCAACACG GAGTACGCCT TCCGCCTGGC GGCCCGCTCG CCGCAGGGCC TGGGCGCCTT 1800 CACCCCCGTG GTGCGGCAGC GCACGCTGCA GTCCAAACCG TCAGCCCCCC CTCAAGACGT 1860 TAAATGTGTC AGCGTGCGCT CCACGGCCAT TTTGGTAAGT TGGCGCCCGC CGCCGCCGGA 1920 AACGCACAAC GGGGCCCTGG TGGGCTACAG CGTCCGCTAC CGACCGCTGG GCTCAGAGGA 1980 CCCGGAACCC AAGGAGGTGA ACGGCATCCC CCCGACCACC ACTCAGATCC TGCTGGAGGC 2040 CTTGGAGAAG TGGACCCAGT ACCGCATCAC GACTGTCGCT CACACAGAGG TGGGACCAGG 2100 GCCCGAGAGC TCGCCCGTGG TCGTCCGCAC CGACGAGGAT GTGCCCAGCG CGCCGCCGCG 2160 GAAGGTGGAG GCGGAGGCGC TCAACGCCAC GGCCATCCGC GTGCTGTGGC GCTCGCCCGC 2220 GCCCGGCCGG CAGCACGGCC AGATCCGCGG CTACCAGGTC CACTACGTGC GCATGGAGGG 2280 CGCCGAGGCC CGCGGGCCGC CGCGCATCAA GGACGTCATG CTGGCCGATG CCCAGGAGAT 2340 GGTCATCACA AACTTGCAGC CTGAGACCGC GTACTCCATC ACGGTAGCCG CCTACACCAT 2400 GAAGGGCGAT GGCGCTCGCA GCAAACCCAA GGTGGTTGTG ACCAAGGGAG CAGTGCTGGG 2460 CCGCCCAACC CTGTCGGTGC AGCAGACCCC CGAGGGCAGC CTGCTGGCAC GCTGGGAGCC 2520 CCCGGCTGGC ACCGCGGAGG ACCAGGTGCT GGGCTACCGC CTGCAGTTTG GCCGTGAGGA 2580 CTCGACGCCC CTGGCCACCC TGGAGTTCCC GCCCTCCGAG GACCGCTACA CGGCATCAGG 2640 CGTGCACAAG GGGGCCACGT ATGTGTTCCG GCTTGCGGCC CGGAGCCCGG GCGGCCTGGG 2700 CGAGGAGGCA GCCGAGGTCC TGAGCATCCC GGAGGACACG CCCCGTGGCC ACCCGCAGAT 2760 TCTGGAGGCG GCCGGCAACG CCTCGGCCGG GACCGTCCTT CTCCGCTGGC TGCCACCCGT 2820 GCCCGCCGAG CGCAACGGGG CCATCGTCAA ATACACGGTG GCCGTGCGGG AGGCCGGTGC 2880 CCTGGGCCCT GCCCGAGAGA CTGAGCTGCC GGCAGGCCGG CTGAGCCGGG CGCGGAGAAC 2940 GCTCACGCTG CAGGGCCTGA AGCCCGACAC GGCCTATGAC CTCCAAGTGC GAGCCCACAC 3000 GCGCCGGGGC CCTGGCCCCT TCAGCCCCCC CGTCCGCTAC CGGACGTTCC TGCGGGACCA 3060 AGTCTCGCCC AAGAACTTCA AGGTGAAAAT GATCATGAAG ACATCAGTTC TGCTCAGCTG 3120 GGAGTTCCCT GACAACTACA ACTCACCCAC ACCCTACAAG ATCCAGTACA ATGGGCTCAC 3180 ACTGGATGTG GATGGCCGTA CCACCAAGAA GCTCATCACG CACCTCAAGC CCCACACCTT 3240 CTACAACTTT GTGCTGACCA ATCGCGGCAG CAGCCTGGGC GGCCTCCAGC AGACGGTCAC 3300 CGCCTGGACT GCCTTCAACC TGCTCAACGG CAAGCCCAGC GTCGCCCCCA AGCCTGATGC 3360 TGACGGCTTC ATCATGGTGT ATCTTCCTGA CGGCCAGAGC CCCGTGCCTG TCCAGAGCTA 3420 TTTCATTGTG ATGGTGCCAC TGCGCAAGTC TCGTGGAGGC CAATTCCTGA CCCCGCTGGG 3480 TAGCCCAGAG GACATGGATC TGGAAGAGCT CATCCAGGAC ATCTCACGGC TACAGAGGCG 3540 CAGCCTGCGG CACTCGCGTC AGCTGGAGGT GCCCCGGCCC TATATTGCAG CTCGCTTCTC 3600 TGTGCTGCCA CCCACGTTCC ATCCCGGCGA CCAGAAGCAG TATGGCGGCT TCGATAACCG 3660 GGGCCTGGAG CCCGGCCACC GCTATGTCCT CTTCGTGCTT GCCGTGCTTC AGAAGAGCGA 3720 GCCTACCTTT GCAGCCAGTC CCTTCTCAGA CCCCTTCCAG CTGGATAACC CGGACCCCCA 3780 GCCCATCGTG GATGGCGAGG AGGGGCTTAT CTGGGTGATC GGGCCTGTGC TGGCCGTGGT 3840 CTTCATAATC TGCATTGTCA TTGCTATCCT GCTCTACAAG AACAAACCCG ACAGTAAACG 3900 CAAGGACTCA GAACCCCGCA CCAAATGCCT CCTGAACAAT GCCGACCTCG CCCCTCACCA 3960 CCCCAAGGAC CCTGTGGAAA TGAGACGCAT TAACTTCCAG ACTCCAGGCA TGCTTAGCCA 4020 CCCGCCAATT CCCATCGCAG ACATGGCGGA GCACACGGAG CGGCTCAAGG CCAACGACAG 4080 CCTCAAGCTC TCCCAGGAGT ATGAGTCCAT CGACCCTGGA CAGCAGTTCA CATGGGAACA 4140 TTCCAACCTG GAAGTGAACA AGCCGAAGAA CCGCTATGCC AACGTCATCG CCTATGACCA 4200 CTCCCGTGTC ATCCTCCAGC CCATTGAAGG CATCATGGGC AGTGATTACA TCAATGCCAA 4260 CTACGTGGAC GGCTACCGGC GTCAGAACGC GTACATTGCC ACGCAGGGGC CGCTGCCTGA 4320 GACCTTTGGG GACTTCTGGC GTATGGTGTG GGAGCAGCGG TCGGCGACCA TCGTCATGAT 4380 GACGCGGCTG GAGGAGAAGT CACGGATCAA GTGTGATCAG TATTGGCCCA ACAGAGGCAC 4440 GGAGACCTAC GGCTTCATCC AGGTCACGTT GCTAGATACC ATCGAGCTGG CCACATTCTG 4500 CGTCAGGACA TTCTCTCTGC ACAAGAATGG CTCCAGTGAG AAACGCGAGG TCCGCCAGTT 4560 CCAGTTTACG GCGTGGCCGG ACCATGGCGT GCCCGAATAC CCAACGCCCT TCCTGGCTTT 4620 CCTGCGGAGA GTCAAGACCT GCAACCCACC AGATGCCGGC CCCATCGTGG TTCACTGCAG 4680 TGCCGGTGTG GGCCGCACAG GCTGCTTTAT CGTCATCGAC GCCATGCTTG AGCGGATCAA 4740 GCCAGAGAAG ACAGTCGATG TCTATGGCCA CGTGACGCTC ATGAGGTCCC AGCGCAACTA 4800 CATGGTGCAG ACGGAGGACC AGTACAGCTT CATCCACGAG GCCCTGCTGG AGGCCGTGGG 4860 CTGTGGCAAC ACAGAAGTGC CCGCACGCAG CCTCTATGCC TACATCCAGA AGCTGGCCCA 4920 GGTGGAGCCT GGCGAACACG TCACTGGCAT GGAACTCGAG TTCAAGCGGC TGGCTAACTC 4980 CAAGGCCCAC ACGTCACGCT TCATCAGTGC CAATCTGCCT TGTAAGAAGT TCAAGAACCG 5040 CCTGGTGAAC ATCATGCCCT ATGAGAGCAC ACGGGTCTGT CTGCAACCCA TCCGGGGTGT 5100 GGAGGGCTCT GACTACATCA ACGCCAGCTT CATTGATGGC TACAGGCAGC AGAAGGCCTA 5160 CATCGCGACA CAGGGGCCGC TGGCGGAGAC CACGGAAGAC TTCTGGCGCA TGCTGTGGGA 5220 GAACAATTCG ACGATCGTGG TGATGCTGAC CAAGCTGCGG GAGATGGGCC GGGAGAAGTG 5280 TCACCAGTAC TGGCCGGCCG AGCGCTCTGC CCGCTACCAG TACTTTGTGG TAGATCCGAT 5340 GGCAGAATAC AACATGCCTC AGTATATCCT GCGAGAGTTC AAGGTCACAG ATGCCCGGGA 5400 TGGCCAGTCC CGGACTGTCC GGCAGTTCCA GTTCACAGAC TGGCCGGAAC AGGGTGTGCC 5460 AAAGTCGGGG GAGGGCTTCA TCGACTTCAT TGGCCAAGTG CATAAGACTA AGGAGCAGTT 5520 TGGCCAGGAC GGCCCCATCT CTGTCCACTG CAGTGCCGGC GTGGGCAGGA CGGGCGTCTT 5580 CATCACGCTT AGCATCGTGC TGGAGCGGAT GCGGTATGAA GGCGTGGTGG ACATCTTTCA 5640 GACGGTGAAG ATGCTACGAA CCCAGCGGCC GGCCATGGTG CAGACAGAGG ATGAGTACCA 5700 GTTCTGTTAC CAGGCGGCAC TGGAGTACCT CGGAAGCTTT GACCACTATG CAACCTAAAG 5760 CCATGGTCCC CCCCAGGCCC GACACCACTG GCCCCGGATG CCTCTGCCCC TCCCGGGCGG 5820 ACCTCCTGAG GCCTGGACCC CCAGTGGGCA GGGCAGGAGG TGGCAGCGGC AGCAGCTGTG 5880 TTTCTGCACC ATTTCCGAGG ACGACGCAGC CCCTCGAGCC CCCCCACCGG CCCCGGCCGC 5940 CCCAGCGACC TCCCTGGCAC GGCCGCCGCC TTCAAATACT TGGCACATTC CCCCGAATTC 6000 WHAT IS CLAIMED IS: 1). An isolated and purified PTP-OB protein wherein said protein specifically expressed in bone cells. 2). The isolated and purified PTP-OB protein of Claim 1 wherein said protein is characterized by the amino acid sequence MAPTWGPGMV SWGPMGLLV VLLVGGCAAE EPPRFIKEPK DQIGVSGRVA SFVCQATGDP KPRVTWNKKG KKVNSQRFET IEFDESAGAV LRIQPLRTPR DENVYECVAQ NSVGEITVHA KLTVLREDQL PSGFPNIDMG PQLKWERTR TATMLCAASG NPDPEITWFK DFLPVDPSAS NGRIKQLRSG ALQIESSEET DQGKYECVAT NSAGVRYSSP ANLYVRVRRV APRFSILPMS HEIMPGGNVN ITCVAVGSPM PYVKWMQGAE DLTPEDDMPV GRNVLELTDV KDSANYHPCV AMSSLGVIEA VAQITVKSLP KAPGTPMVTE NTATSITITW DSGNPDPVSY YVIEYKSKSQ DGPYQIKEDI TTTRYSIGGL SPNSEYEIWV SAVNSIGQGP PSESWTRTG EQAPARPPRN VQARMLSATT MIVQWEEPVE PNGLIRGYRV YYTMEPEHPV GNWQKHNVDD SLLTTVGSLL EDETYTVRVL AFTSVGDGPL SDPIQVKTQQ GVPGQPMNLR AEARSETSIT LSWSPPRQES IIKYELLFRE GDHGREVGRT FDPTTSYWE DLKPNTEYAF RLAARSPQGL GAFTPWRQR TLQSKPSAPP QDVKCVSVRS TAILVSWRPP PPETHNGALV GYSVRYRPLG SEDPEPKEVN GIPPTTTQIL LEALEKWTQY RITTVAHTEV GPGPESSPW VRTDEDVPSA PPRKVEAEAL NATAIRVLWR SPAPGRQHGQ IRGYQVHYVR MEGAEARGPP RIKDVMLADA QEMVITNLQP ETAYSITVAA YTMKGDGARS KPKVWTKGA VLGRPTLSVQ QTPEGSLLAR WEPPAGTAED QVLGYRLQFG REDSTPLATL EFPPSEDRYT ASGVHKGATY VFRLAARSPG GLGEEAAEVL ΞIPEDTPRGH PQILEAAGNA SAGTVLLRWL PPVPAERNGA IVKYTVAVRE AGALGPARET ELPAGRLSRA RRTLTLQGLK PDTAYDLQVR AHTRRGPGPF SPPVRYRTFL RDQVSPKNFK VKMIMKTSVL LSWEFPDNYN SPTPYKIQYN GLTLDVDGRT TKKLITHLKP HTFYNFVLTN RGSSLGGLQQ TVTAWTAFNL LNGKPSVAPK PDADGFIMVY LPDGQSPVPV QSYFIVMVPL RKSRGGQFLT PLGSPEDMDL EELIQDISRL QRRSLRHSRQ LEVPRPYIAA RFSVLPPTFH PGDQKQYGGF DNRGLEPGHR YVLFVLAVLQ KSEPTFAASP FSDPFQLDNP DPQPIVDGEE GLIWVIGPVL AWFIICIVI AILLYKNKPD SKRKDSEPRT KCLLNNADLA PHHPKDPVEM RRINFQTPGM LSHPPIPIAD MAEHTERLKA NDSLKLSQEY ESIDPGQQFT WEHSNLEVNK PKNRYANVIA YDHSRVILQP IEGIMGSDYI NANYVDGYRR QNAYIATQGP LPETFGDFWR MVWEQRSATI VMMTRLEEKS RIKCDQYWPN RGTETYGFIQ VTLLDTIELA TFCVRTFSLH KNGSSEKREV RQFQFTAWPD HGVPEYPTPF LAFLRRVKTC NPPDAGPIW HCSAGVGRTG CFIVIDAMLE RIKPEKTVDV YGHVTLMRSQ RNYMVQTEDQ YSFIHEALLE AVGCGNTEVP ARSLYAYIQK LAQVEPGEHV TGMELEFKRL ANSKAHTSRF ISANLPCKKF KNRLVNIMPY ESTRVCLQPI RGVEGSDYIN

Claims: ASFIDGYRQQ KAYIATQGPL AETTEDFWRM LWENNSTIW MLTKLREMGR EKCHQYWPAE RSARYQYFW DPMAEYNMPQ YILREFKVTD ARDGQSRTVR QFQFTDWPEQ GVPKSGEGFI DFIGQVHKTK EQFGQDGPIS VHCSAGVGRT GVFITLSIVL ERMRYEGWD IFQTVKMLRT QRPAMVQTED EYQFCYQAAL EYLGSFDHYA T (SEQ.ID.NO. :5) . 3). An isolated and purified DNA molecule encoding a PTP-OB protein wherein said protein is characterized by the amino acid sequence of Claim 2. 4). An isolated and purified DNA molecule encoding a PTP-OB protein wherein said DNA molecule is characterized by the nucleotide sequence GAATTCCGGG TCGCTGCCAA GCATGGCGCC CACCTGGGGC CCTGGCATGG TGTCTGTGGT TGGTCCCATG GGCCTCCTTG TGGTCCTGCT CGTTGGAGGC TGTGCAGCAG AAGAGCCCCC CAGGTTTATC AAAGAACCCA AGGACCAGAT CGGCGTGTCG GGGCGTGTGG CCTCTTTCGT GTGTCAGGCC ACGGGTGACC CCAAGCCACG AGTGACCTGG AACAAGAAGG GCAAGAAGGT CAACTCTCAG CGCTTTGAGA CGATTGAGTT TGATGAGAGT GCAGGGGCAG TGCTGAGGAT CCAGCCGCTG AGGACACCGC GGGATGAAAA CGTGTACGAG TGTGTGGCCC AGAACTCGGT TGGGGAGATC ACAGTCCATG CCAAGCTTAC TGTCCTCCGA GAGGACCAGC TGCCCTCTGG CTTCCCCAAC ATCGACATGG GCCCACAGTT GAAGGTGGTG GAGCGGACAC GGACAGCCAC CATGCTCTGT GCAGCCAGCG GCAACCCTGA CCCTGAGATC ACCTGGTTCA AGGACTTCCT GCCTGTGGAT CCTAGTGCCA GCAATGGACG CATCAAACAG CTGCGATCAG GAGCCCTGCA GATTGAAAGC AGTGAGGAAA CCGACCAGGG CAAATATGAG TGTGTGGCCA CCAACAGCGC CGGCGTGCGC TACTCCTCAC CTGCCAACCT CTACGTGCGA GTCCGCCGCG TGGCCCCGCG CTTCTCCATC CTGCCCATGA GCCACGAGAT CATGCCAGGG GGCAACGTGA ACATCACCTG CGTGGCCGTG GGCTCGCCCA TGCCATACGT GAAGTGGATG CAGGGGGCCG AGGACCTGAC CCCCGAGGAT GACATGCCCG TGGGTCGGAA CGTGCTGGAA CTCACAGATG TCAAGGACTC GGCCAACTAC CACCCCTGCG TGGCCATGTC CAGCCTGGGC GTCATTGAGG CGGTTGCTCA GATCACGGTG AAATCTCTCC CCAAAGCTCC CGGGACTCCC ATGGTGACTG AGAACACAGC CACCAGCATC ACCATCACGT GGGACTCGGG CAACCCAGAT CCTGTGTCCT ATTACGTCAT CGAATATAAA TCCAAGAGCC AAGACGGGCC GTATCAGATT AAAGAGGACA TCACCACCAC ACGTTACAGC ATCGGCGGCC TGAGCCCCAA CTCGGAGTAC GAGATCTGGG TGTCGGCCGT CAACTCCATC GGCCAGGGGC CCCCCAGCGA GTCCGTGGTC ACCCGCACAG GCGAGCAGGC CCCGGCCAGG CCGCCGCGGA ACGTGCAAGC CCGGATGCTC AGCGCGACCA CCATGATTGT GCAGTGGGAG GAGCCGGTGG AGCCCAACGG CCTGATCCGC GGCTACCGCG TCTACTACAC CATGGAACCG GAGCACCCCG TGGGCAACTG GCAGAAGCAC AACGTGGACG ACAGCCTGCT GACCACCGTG GGCAGCCTGC TGGAGGACGA GACCTACACC GTGCGGGTGC TCGCCTTCAC CTCCGTCGGC GACGGGCCCC TCTCGGACCC CATCCAGGTC AAGACGCAGC AGGGAGTGCC GGGCCAGCCC ATGAACCTGC GGGCCGAGGC CAGGTCGGAG ACCAGCATCA CGCTGTCCTG GAGCCCCCCG CGGCAGGAGA GTATCATCAA GTACGAGCTC CTCTTCCGGG AAGGCGACCA TGGCCGGGAG GTGGGAAGGA CCTTCGACCC GACGACTTCC TACGTGGTGG AGGACCTGAA GCCCAACACG GAGTACGCCT TCCGCCTGGC GGCCCGCTCG CCGCAGGGCC TGGGCGCCTT CACCCCCGTG GTGCGGCAGC GCACGCTGCA GTCCAAACCG TCAGCCCCCC CTCAAGACGT TAAATGTGTC AGCGTGCGCT CCACGGCCAT TTTGGTAAGT TGGCGCCCGC CGCCGCCGGA AACGCACAAC GGGGCCCTGG TGGGCTACAG CGTCCGCTAC CGACCGCTGG GCTCAGAGGA CCCGGAACCC AAGGAGGTGA ACGGCATCCC CCCGACCACC ACTCAGATCC TGCTGGAGGC CTTGGAGAAG TGGACCCAGT ACCGCATCAC GACTGTCGCT CACACAGAGG TGGGACCAGG GCCCGAGAGC TCGCCCGTGG TCGTCCGCAC CGACGAGGAT GTGCCCAGCG CGCCGCCGCG GAAGGTGGAG GCGGAGGCGC TCAACGCCAC GGCCATCCGC GTGCTGTGGC GCTCGCCCGC GCCCGGCCGG CAGCACGGCC AGATCCGCGG CTACCAGGTC CACTACGTGC GCATGGAGGG CGCCGAGGCC CGCGGGCCGC CGCGCATCAA GGACGTCATG CTGGCCGATG CCCAGGAGAT GGTCATCACA AACTTGCAGC CTGAGACCGC GTACTCCATC ACGGTAGCCG CCTACACCAT GAAGGGCGAT GGCGCTCGCA GCAAACCCAA GGTGGTTGTG ACCAAGGGAG CAGTGCTGGG CCGCCCAACC CTGTCGGTGC AGCAGACCCC CGAGGGCAGC CTGCTGGCAC GCTGGGAGCC CCCGGCTGGC ACCGCGGAGG ACCAGGTGCT GGGCTACCGC CTGCAGTTTG GCCGTGAGGA CTCGACGCCC CTGGCCACCC TGGAGTTCCC GCCCTCCGAG GACCGCTACA CGGCATCAGG CGTGCACAAG GGGGCCACGT ATGTGTTCCG GCTTGCGGCC CGGAGCCCGG GCGGCCTGGG CGAGGAGGCA GCCGAGGTCC TGAGCATCCC GGAGGACACG CCCCGTGGCC ACCCGCAGAT TCTGGAGGCG GCCGGCAACG CCTCGGCCGG GACCGTCCTT CTCCGCTGGC TGCCACCCGT GCCCGCCGAG CGCAACGGGG CCATCGTCAA ATACACGGTG GCCGTGCGGG AGGCCGGTGC CCTGGGCCCT GCCCGAGAGA CTGAGCTGCC GGCAGGCCGG CTGAGCCGGG CGCGGAGAAC GCTCACGCTG CAGGGCCTGA AGCCCGACAC GGCCTATGAC CTCCAAGTGC GAGCCCACAC GCGCCGGGGC CCTGGCCCCT TCAGCCCCCC CGTCCGCTAC CGGACGTTCC TGCGGGACCA AGTCTCGCCC AAGAACTTCA AGGTGAAAAT GATCATGAAG ACATCAGTTC TGCTCAGCTG GGAGTTCCCT GACAACTACA ACTCACCCAC ACCCTACAAG ATCCAGTACA ATGGGCTCAC ACTGGATGTG GATGGCCGTA CCACCAAGAA GCTCATCACG CACCTCAAGC CCCACACCTT CTACAACTTT GTGCTGACCA ATCGCGGCAG CAGCCTGGGC GGCCTCCAGC AGACGGTCAC CGCCTGGACT GCCTTCAACC TGCTCAACGG CAAGCCCAGC GTCGCCCCCA AGCCTGATGC TGACGGCTTC ATCATGGTGT ATCTTCCTGA CGGCCAGAGC CCCGTGCCTG TCCAGAGCTA TTTCATTGTG ATGGTGCCAC TGCGCAAGTC TCGTGGAGGC CAATTCCTGA CCCCGCTGGG TAGCCCAGAG GACATGGATC TGGAAGAGCT CATCCAGGAC ATCTCACGGC TACAGAGGCG CAGCCTGCGG CACTCGCGTC AGCTGGAGGT GCCCCGGCCC TATATTGCAG CTCGCTTCTC TGTGCTGCCA CCCACGTTCC ATCCCGGCGA CCAGAAGCAG TATGGCGGCT TCGATAACCG GGGCCTGGAG CCCGGCCACC GCTATGTCCT CTTCGTGCTT GCCGTGCTTC AGAAGAGCGA GCCTACCTTT GCAGCCAGTC CCTTCTCAGA CCCCTTCCAG CTGGATAACC CGGACCCCCA GCCCATCGTG GATGGCGAGG AGGGGCTTAT CTGGGTGATC GGGCCTGTGC TGGCCGTGGT CTTCATAATC TGCATTGTCA TTGCTATCCT GCTCTACAAG AACAAACCCG ACAGTAAACG CAAGGACTCA GAACCCCGCA CCAAATGCCT CCTGAACAAT GCCGACCTCG CCCCTCACCA CCCCAAGGAC CCTGTGGAAA TGAGACGCAT TAACTTCCAG ACTCCAGGCA TGCTTAGCCA CCCGCCAATT CCCATCGCAG ACATGGCGGA GCACACGGAG CGGCTCAAGG CCAACGACAG CCTCAAGCTC TCCCAGGAGT ATGAGTCCAT CGACCCTGGA CAGCAGTTCA CATGGGAACA TTCCAACCTG GAAGTGAACA AGCCGAAGAA CCGCTATGCC AACGTCATCG CCTATGACCA CTCCCGTGTC ATCCTCCAGC CCATTGAAGG CATCATGGGC AGTGATTACA TCAATGCCAA CTACGTGGAC GGCTACCGGC GTCAGAACGC GTACATTGCC ACGCAGGGGC CGCTGCCTGA GACCTTTGGG GACTTCTGGC GTATGGTGTG GGAGCAGCGG TCGGCGACCA TCGTCATGAT GACGCGGCTG GAGGAGAAGT CACGGATCAA GTGTGATCAG TATTGGCCCA ACAGAGGCAC GGAGACCTAC GGCTTCATCC AGGTCACGTT GCTAGATACC ATCGAGCTGG CCACATTCTG CGTCAGGACA TTCTCTCTGC ACAAGAATGG CTCCAGTGAG AAACGCGAGG TCCGCCAGTT CCAGTTTACG GCGTGGCCGG ACCATGGCGT GCCCGAATAC CCAACGCCCT TCCTGGCTTT CCTGCGGAGA GTCAAGACCT GCAACCCACC AGATGCCGGC CCCATCGTGG TTCACTGCAG TGCCGGTGTG GGCCGCACAG GCTGCTTTAT CGTCATCGAC GCCATGCTTG AGCGGATCAA GCCAGAGAAG ACAGTCGATG TCTATGGCCA CGTGACGCTC ATGAGGTCCC AGCGCAACTA CATGGTGCAG ACGGAGGACC AGTACAGCTT CATCCACGAG GCCCTGCTGG AGGCCGTGGG CTGTGGCAAC ACAGAAGTGC CCGCACGCAG CCTCTATGCC TACATCCAGA AGCTGGCCCA GGTGGAGCCT GGCGAACACG TCACTGGCAT GGAACTCGAG TTCAAGCGGC TGGCTAACTC CAAGGCCCAC ACGTCACGCT TCATCAGTGC CAATCTGCCT TGTAAGAAGT TCAAGAACCG CCTGGTGAAC ATCATGCCCT ATGAGAGCAC ACGGGTCTGT CTGCAACCCA TCCGGGGTGT GGAGGGCTCT GACTACATCA ACGCCAGCTT CATTGATGGC TACAGGCAGC AGAAGGCCTA CATCGCGACA CAGGGGCCGC TGGCGGAGAC CACGGAAGAC TTCTGGCGCA TGCTGTGGGA GAACAATTCG ACGATCGTGG TGATGCTGAC CAAGCTGCGG GAGATGGGCC GGGAGAAGTG TCACCAGTAC TGGCCGGCCG AGCGCTCTGC CCGCTACCAG TACTTTGTGG TAGATCCGAT GGCAGAATAC AACATGCCTC AGTATATCCT GCGAGAGTTC AAGGTCACAG ATGCCCGGGA TGGCCAGTCC CGGACTGTCC GGCAGTTCCA GTTCACAGAC TGGCCGGAAC AGGGTGTGCC AAAGTCGGGG GAGGGCTTCA TCGACTTCAT TGGCCAAGTG CATAAGACTA AGGAGCAGTT TGGCCAGGAC GGCCCCATCT CTGTCCACTG CAGTGCCGGC GTGGGCAGGA CGGGCGTCTT CATCACGCTT AGCATCGTGC TGGAGCGGAT GCGGTATGAA GGCGTGGTGG ACATCTTTCA GACGGTGAAG ATGCTACGAA CCCAGCGGCC GGCCATGGTG CAGACAGAGG ATGAGTACCA GTTCTGTTAC CAGGCGGCAC TGGAGTACCT CGGAAGCTTT GACCACTATG CAACCTAAAG CCATGGTCCC CCCCAGGCCC GACACCACTG GCCCCGGATG CCTCTGCCCC TCCCGGGCGG ACCTCCTGAG GCCTGGACCC CCAGTGGGCA GGGCAGGAGG TGGCAGCGGC AGCAGCTGTG TTTCTGCACC ATTTCCGAGG ACGACGCAGC CCCTCGAGCC CCCCCACCGG CCCCGGCCGC CCCAGCGACC TCCCTGGCAC GGCCGCCGCC TTCAAATACT TGGCACATTC CCCCGAATTC (SEQ.ID.NO. : 6) . 5). An expression vector for the expression of a PTP-OB protein in a recombinant host cell wherein said expression vector contains the DNA molecule of Claim 4. 6). A host cell which expresses a recombinant PTP-OB protein wherein said host cell contains the expression vector of claim 5. 7). A process for the expression of a PTP-OB protein in a recombinant host cell, comprising: (a) transferring the expression vector of claim 5 into a suitable host cell; and (b) culturing the host cells of step (a) under conditions which allow expression of the receptor protein from the expression vector. 8). A method of identifying modulators of a PTP-OB protein activity, comprising: (a) combining a modulator of PTP-OB protein activity, with a PTP-OB protein wherein said PTP-OB protein is characterized by the amino acid sequence of Claim 2 in whole or in part; and (b) measuring the effect of a modulator on the PTP- OB protein. 9). An antibody which specifically binds to a PTP-OB protein wherein said protein is characterized by the amino acid sequence of Claim 2. 10). A method of modulating osteoclast formation and activity using a modulator of PTP-OB.

Inventors: RODAN GIDEON A, RUTLEDGE SU JANE, SCHMIDT AZRIEL, RODAN, GIDEON, A., RUTLEDGE, SU, JANE, SCHMIDT, AZRIEL
Applicants: MERCK & CO INC, RODAN GIDEON A, RUTLEDGE SU JANE, SCHMIDT AZRIEL, MERCK & CO., INC., RODAN, GIDEON, A., RUTLEDGE, SU, JANE, SCHMIDT, AZRIEL
Application year: 1994
Main classification: C07K16
IPC codes: C07K16, C12N5, C12N9, C12N15, C12Q1, C12R1